1
|
Vercouillie J, Buron F, Sérrière S, Rodrigues N, Gulhan Z, Chartier A, Chicheri G, Marzag H, Oury A, Percina N, Bodard S, Ben Othman R, Busson J, Suzenet F, Guilloteau D, Marchivie M, Emond P, Routier S, Chalon S. Development and preclinical evaluation of [18F]FBVM as a new potent PET tracer for vesicular acetylcholine transporter. Eur J Med Chem 2022; 244:114794. [DOI: 10.1016/j.ejmech.2022.114794] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/10/2022] [Revised: 09/13/2022] [Accepted: 09/23/2022] [Indexed: 11/30/2022]
|
2
|
Vercouillie J, Buron F, Serriere S, Rodriguez N, Gulhan Z, Chartier A, Chicheri G, Oury A, Bodard S, Busson J, Suzenet F, Guilloteau D, Marchivie M, Emond P, Routier S, Chalon S. Preclinical evaluation of [18F]FBVM as a new potent PET tracer for vesicular acetylcholine transporter. Nucl Med Biol 2022. [DOI: 10.1016/s0969-8051(22)00246-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
3
|
Vala C, Mothes C, Chicheri G, Magadur P, Viot G, Deloye JB, Maia S, Bouvet Y, Dupont AC, Arlicot N, Guilloteau D, Emond P, Vercouillie J. Fully automated radiosynthesis of [ 18F]LBT999 on TRACERlab FX FN and AllinOne modules, a PET radiopharmaceutical for imaging the dopamine transporter in human brain. EJNMMI Radiopharm Chem 2020; 5:26. [PMID: 33196944 PMCID: PMC7669936 DOI: 10.1186/s41181-020-00105-w] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/16/2020] [Accepted: 10/19/2020] [Indexed: 11/30/2022] Open
Abstract
Background Fluorine labelled 8-((E)-4-fluoro-but-2-enyl)-3β-p-tolyl-8-aza-bicyclo[3.2.1]octane-2β-carboxylic acid methyl ester ([18F]LBT999) is a selective radioligand for the in vivo neuroimaging and quantification of the dopamine transporter by Positron Emission Tomography (PET). [18F]LBT999 was produced on a TRACERlab FXFN for the Phase I study but for Phase III and a potent industrial production transfer, production was also implemented on an AllinOne (AIO) system requiring a single use cassette. Both production methods are reported herein. Results Automation of [18F]LBT999 radiosynthesis on FXFN was carried out in 35% yield (decay-corrected) in 65 min (n = 16), with a radiochemical purity higher than 99% and a molar activity of 158 GBq/μmol at the end of synthesis. The transfer to the AIO platform followed by optimizations allowed the production of [18F]LBT999 in 32.7% yield (decay-corrected) within 48 min (n = 5), with a radiochemical purity better than 98% and a molar activity above 154 GBq/μmol on average at the end of synthesis. Quality controls of both methods met the specification for clinical application. Conclusion Both modules allow efficient and reproducible radiosynthesis of [18F]LBT999 with good radiochemical yields and a reasonable synthesis time. The developments made on AIO, such as its ability to meet pharmaceutical criteria and to more easily comply with GMP requirements, make it an optimal approach for the potent industrial production of [18F]LBT999 and future wider use.
Collapse
Affiliation(s)
- Christine Vala
- Zionexa, 75017, Paris, France.,Cyclopharma, 63360, Saint-Beauzire, France.,CERRP, 37100, Tours, France
| | - Céline Mothes
- Zionexa, 75017, Paris, France.,Cyclopharma, 63360, Saint-Beauzire, France.,CERRP, 37100, Tours, France
| | - Gabrielle Chicheri
- CERRP, 37100, Tours, France.,UMR 1253, iBrain, Université de Tours, Inserm, 37000, Tours, France
| | - Pauline Magadur
- Cyclopharma, 63360, Saint-Beauzire, France.,CERRP, 37100, Tours, France
| | | | - Jean-Bernard Deloye
- Zionexa, 75017, Paris, France.,Cyclopharma, 63360, Saint-Beauzire, France.,CERRP, 37100, Tours, France
| | - Serge Maia
- CERRP, 37100, Tours, France.,UMR 1253, iBrain, Université de Tours, Inserm, 37000, Tours, France.,INSERM CIC 1415, University Hospital, 37000, Tours, France.,CHRU de Tours, services de Médecine Nucléaire in vitro et in vivo, 37000, Tours, France
| | - Yann Bouvet
- Zionexa, 75017, Paris, France.,Cyclopharma, 63360, Saint-Beauzire, France
| | - Anne-Claire Dupont
- CERRP, 37100, Tours, France.,UMR 1253, iBrain, Université de Tours, Inserm, 37000, Tours, France.,INSERM CIC 1415, University Hospital, 37000, Tours, France.,CHRU de Tours, services de Médecine Nucléaire in vitro et in vivo, 37000, Tours, France
| | - Nicolas Arlicot
- CERRP, 37100, Tours, France.,UMR 1253, iBrain, Université de Tours, Inserm, 37000, Tours, France.,INSERM CIC 1415, University Hospital, 37000, Tours, France.,CHRU de Tours, services de Médecine Nucléaire in vitro et in vivo, 37000, Tours, France
| | - Denis Guilloteau
- CERRP, 37100, Tours, France.,UMR 1253, iBrain, Université de Tours, Inserm, 37000, Tours, France.,INSERM CIC 1415, University Hospital, 37000, Tours, France.,CHRU de Tours, services de Médecine Nucléaire in vitro et in vivo, 37000, Tours, France
| | - Patrick Emond
- CERRP, 37100, Tours, France.,UMR 1253, iBrain, Université de Tours, Inserm, 37000, Tours, France.,CHRU de Tours, services de Médecine Nucléaire in vitro et in vivo, 37000, Tours, France
| | - Johnny Vercouillie
- CERRP, 37100, Tours, France. .,UMR 1253, iBrain, Université de Tours, Inserm, 37000, Tours, France. .,INSERM CIC 1415, University Hospital, 37000, Tours, France.
| |
Collapse
|
4
|
Ribeiro MJ, Vercouillie J, Arlicot N, Tauber C, Gissot V, Mondon K, Barantin L, Cottier JP, Maia S, Deloye JB, Emond P, Guilloteau D. Usefulness of PET With [ 18F]LBT-999 for the Evaluation of Presynaptic Dopaminergic Neuronal Loss in a Clinical Environment. Front Neurol 2020; 11:754. [PMID: 32973645 PMCID: PMC7472558 DOI: 10.3389/fneur.2020.00754] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/21/2020] [Accepted: 06/18/2020] [Indexed: 11/21/2022] Open
Abstract
Purpose: The density of the neuronal dopamine transporter (DAT) is directly correlated with the presynaptic dopaminergic system injury. In a first study, we evaluated the brain distribution and kinetics of [18F]LBT-999, a DAT PET radioligand, in a group of eight healthy subjects. Taking into account the results obtained in healthy volunteers, we wanted to evaluate whether the loss of presynaptic striatal dopaminergic fibers could be estimated, under routine clinical conditions, using [18F]LBT-999 and a short PET acquisition. Materials and methods: Six patients with Parkinson's disease (PD) were compared with eight controls. Eighty-nine minutes of dynamic PET following an intravenous injection of [18F]LBT-999 were acquired. Using regions of interest for striatal nuclei, substantia nigra (SN), cerebellum, and occipital cortex, defined over each T1 3D MRI, time–activity curves (TACs) were obtained. From TACs, binding potential (BPND) using the simplified reference tissue model and distribution volume ratios (DVRs) using Logan graphical analysis were calculated. Ratios obtained for a 10-min image, acquired between 30 and 40 min post-injection, were also calculated. Cerebellum activity was used as non-specific reference region. Results: In PD patients and as expected, striatal uptake was lower than in controls which is confirmed by BPND, DVR, and ratios calculated for both striatal nuclei and SN, significantly inferior in PD patients compared with controls (p < 0.001). Conclusions: PET with [18F]LBT-999 could be an alternative to assess dopaminergic presynaptic injury in a clinical environment using a single 10 min acquisition.
Collapse
Affiliation(s)
- Maria-Joao Ribeiro
- UMR 1253, iBrain, Université de Tours, Tours, France.,CHRU, Tours, France.,Inserm CIC 1415, CHRU, Tours, France
| | - Johnny Vercouillie
- UMR 1253, iBrain, Université de Tours, Tours, France.,CHRU, Tours, France.,Inserm CIC 1415, CHRU, Tours, France
| | - Nicolas Arlicot
- UMR 1253, iBrain, Université de Tours, Tours, France.,CHRU, Tours, France.,Inserm CIC 1415, CHRU, Tours, France
| | - Clovis Tauber
- UMR 1253, iBrain, Université de Tours, Tours, France
| | - Valérie Gissot
- CHRU, Tours, France.,Inserm CIC 1415, CHRU, Tours, France
| | | | - Laurent Barantin
- UMR 1253, iBrain, Université de Tours, Tours, France.,CHRU, Tours, France
| | | | | | | | - Patrick Emond
- UMR 1253, iBrain, Université de Tours, Tours, France.,CHRU, Tours, France
| | - Denis Guilloteau
- UMR 1253, iBrain, Université de Tours, Tours, France.,CHRU, Tours, France.,Inserm CIC 1415, CHRU, Tours, France
| |
Collapse
|
5
|
Ouach A, Vercouillie J, Bertrand E, Rodrigues N, Pin F, Serriere S, Boiaryna L, Chartier A, Percina N, Tangpong P, Gulhan Z, Mothes C, Deloye JB, Guilloteau D, Page G, Suzenet F, Buron F, Chalon S, Routier S. Bis(het)aryl-1,2,3-triazole quinuclidines as α7 nicotinic acetylcholine receptor ligands: Synthesis, structure affinity relationships, agonism activity, [18F]-radiolabeling and PET study in rats. Eur J Med Chem 2019; 179:449-469. [DOI: 10.1016/j.ejmech.2019.06.049] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/29/2019] [Revised: 06/16/2019] [Accepted: 06/17/2019] [Indexed: 12/12/2022]
|
6
|
Arlicot N, Vercouillie J, Malherbe C, Bidault R, Gissot V, Maia S, Barantin L, Cottier JP, Deloye JB, Guilloteau D, Ribeiro MJ. PET imaging of Dopamine Transporter with [18F]LBT-999: initial evaluation in healthy volunteers. Q J Nucl Med Mol Imaging 2019; 66:148-155. [PMID: 31496203 DOI: 10.23736/s1824-4785.19.03175-3] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
BACKGROUND To evaluate in healthy human brain the distribution, uptake, and kinetics of [18F]LBT-999, a PET ligand targeting the dopamine transporter, to assess its ability to explore dopaminergic innervation, using a shorter protocol, more convenient for patients than currently with [123I]ioflupane. METHODS After intravenous injection of [18F]LBT-999, 8 healthy subjects (53-80y) underwent a dynamic PET-scan. Venous samples were concomitantly obtained for metabolites analysis. Time activity curves (TACs) were generated for several ROIs (caudate, putamen, occipital cortex, substantia nigra and cerebellum). Cerebellum was used as reference region to calculate binding potentials (BPND). RESULTS No adverse events or detectable pharmacological effects were reported. [18F]LBT-999 PET revealed a good cerebral distribution, with an intense and symmetric uptake in both putamen and caudate (BPND of 6.75±1.17 and 6.30±1.17, respectively), without other brain abnormal tracer accumulation. Regional TACs showed a plateau from the maximal uptake, 20min pi, to the end of the acquisition for both caudate and putamen, whereas uptake in substantia nigra decreased progressively. A faster clearance and lowest BPND values were observed in both cortex and cerebellum. Ratios to the cerebellum exhibit value of about 3 in substantia nigra, close to 10 for both caudate and putamen, and remained around the value of 1 in cortex. The parent fraction of [18F]LBT-999 in plasma was 80%, 60% and 45% at 15, 30 and 45 min pi, respectively. CONCLUSIONS These findings support the usefulness of [18F]LBT-999 for a quantitative clinical evaluation of presynaptic dopaminergic innervation.
Collapse
Affiliation(s)
- Nicolas Arlicot
- CHRU de Tours, Unité de Radiopharmacie, Tours, France - .,UMR 1253, iBrain, Université de Tours, Inserm, Tours, France - .,-INSERM CIC 1415, University Hospital, Tours, France -
| | - Johnny Vercouillie
- UMR 1253, iBrain, Université de Tours, Inserm, Tours, France.,-INSERM CIC 1415, University Hospital, Tours, France
| | - Cécile Malherbe
- CHRU de Tours, Unité de Radiopharmacie, Tours, France.,UMR 1253, iBrain, Université de Tours, Inserm, Tours, France
| | - Rudy Bidault
- UMR 1253, iBrain, Université de Tours, Inserm, Tours, France
| | | | - Serge Maia
- CHRU de Tours, Unité de Radiopharmacie, Tours, France.,UMR 1253, iBrain, Université de Tours, Inserm, Tours, France
| | | | - Jean-Philippe Cottier
- UMR 1253, iBrain, Université de Tours, Inserm, Tours, France.,CHRU de Tours, Service de Neuroradiologie, Tours, France
| | | | - Denis Guilloteau
- UMR 1253, iBrain, Université de Tours, Inserm, Tours, France.,-INSERM CIC 1415, University Hospital, Tours, France.,CHRU de Tours, Service de Médecine Nucléaire in vitro, Tours, France
| | - Maria-Joao Ribeiro
- UMR 1253, iBrain, Université de Tours, Inserm, Tours, France.,-INSERM CIC 1415, University Hospital, Tours, France.,CHRU de Tours, Service de Médecine Nucléaire in vivo, Tours, France
| |
Collapse
|
7
|
Chalon S, Vercouillie J, Payoux P, Deloye JB, Malherbe C, Le Jeune F, Arlicot N, Salabert AS, Guilloteau D, Emond P, Ribeiro MJ. The Story of the Dopamine Transporter PET Tracer LBT-999: From Conception to Clinical Use. Front Med (Lausanne) 2019; 6:90. [PMID: 31131278 PMCID: PMC6509245 DOI: 10.3389/fmed.2019.00090] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/25/2019] [Accepted: 04/10/2019] [Indexed: 12/19/2022] Open
Abstract
The membrane dopamine transporter (DAT) is involved in a number of brain disorders and its exploration by positron emission tomography (PET) imaging is highly relevant for the early and differential diagnosis, follow-up and treatment assessment of these diseases. A number of carbon-11 and fluor-18 labeled tracers are to date available for this aim, the majority of them being derived from the chemical structure of cocaine. The development of such a tracer, from its conception to its use, is a long process, the expected result being to obtain the best radiopharmaceutical adapted for clinical protocols. In this context, the cocaine derivative (E)-N-(4-fluorobut-2-enyl)2β-carbomethoxy-3β-(4′-tolyl)nortropane, or LBT-999, has passed all the required stages of the development that makes it now a highly relevant imaging tool, particularly in the context of Parkinson's disease. This review describes the different steps of the development of LBT-999 which initially came from its non-fluorinated derivative (E)-N-(3-iodoprop-2-enyl)-2-carbomethoxy-3-(4-methylphenyl) nortropane, or PE2I, because of its high promising properties. [18F]LBT-999 has been extensively characterized in rodent and non-human primate models, in which it demonstrated its capability to explore in vivo the DAT localized at the dopaminergic nerve endings as well as at the mesencephalic cell bodies, in physiological conditions. In lesion-induced rat models of Parkinson's disease, [18F]LBT-999 was able to precisely quantify in vivo the dopaminergic neuron loss, and to assess the beneficial effects of therapeutic approaches such as pharmacological treatment and cell transplantation. Finally recent clinical data demonstrated the efficiency of [18F]LBT-999 in the diagnosis of Parkinson's disease.
Collapse
Affiliation(s)
- Sylvie Chalon
- UMR 1253, iBrain, Université de Tours, Inserm, Tours, France
| | - Johnny Vercouillie
- UMR 1253, iBrain, Université de Tours, Inserm, Tours, France.,Inserm CIC 1415, University Hospital, Tours, France
| | - Pierre Payoux
- ToNIC, Toulouse NeuroImaging Center, Université de Toulouse, Inserm, UPS, Toulouse, France.,University Hospital, Nuclear Medicine Unit, Toulouse, France
| | | | - Cécile Malherbe
- UMR 1253, iBrain, Université de Tours, Inserm, Tours, France
| | - Florence Le Jeune
- University of Rennes 1, Rennes, France.,Department of Nuclear Medicine, Centre Eugène Marquis, Rennes, France
| | - Nicolas Arlicot
- UMR 1253, iBrain, Université de Tours, Inserm, Tours, France.,Inserm CIC 1415, University Hospital, Tours, France.,CHRU Tours, Tours, France
| | - Anne-Sophie Salabert
- ToNIC, Toulouse NeuroImaging Center, Université de Toulouse, Inserm, UPS, Toulouse, France.,University Hospital, Nuclear Medicine Unit, Toulouse, France
| | - Denis Guilloteau
- UMR 1253, iBrain, Université de Tours, Inserm, Tours, France.,CHRU Tours, Tours, France
| | - Patrick Emond
- UMR 1253, iBrain, Université de Tours, Inserm, Tours, France.,CHRU Tours, Tours, France
| | - Maria-Joao Ribeiro
- UMR 1253, iBrain, Université de Tours, Inserm, Tours, France.,Inserm CIC 1415, University Hospital, Tours, France.,CHRU Tours, Tours, France
| |
Collapse
|
8
|
Malherbe C, Bidault R, Netter C, Guilloteau D, Vercouillie J, Arlicot N. Development of a Fast and Facile Analytical Approach to Quantify Radiometabolites in Human Plasma Samples Using Ultra High Performance Liquid Chromatography. ACTA ACUST UNITED AC 2019. [DOI: 10.4236/ajac.2019.105016] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
|
9
|
Elie J, Vercouillie J, Arlicot N, Lemaire L, Bidault R, Bodard S, Hosselet C, Deloye JB, Chalon S, Emond P, Guilloteau D, Buron F, Routier S. Design of selective COX-2 inhibitors in the (aza)indazole series. Chemistry, in vitro studies, radiochemistry and evaluations in rats of a [ 18F] PET tracer. J Enzyme Inhib Med Chem 2018; 34:1-7. [PMID: 30362376 PMCID: PMC6211253 DOI: 10.1080/14756366.2018.1501043] [Citation(s) in RCA: 19] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022] Open
Abstract
A series of novel derivatives exhibiting high affinity and selectivity towards the COX-2 enzyme in the (aza) indazole series was developed. A short synthetic route involving a bromination/arylation sequence under microwave irradiation and direct C–H activation were established in the indazole and azaindazole series respectively. In vitro assays were conducted and structural modifications were carried out on these scaffolds to furnish compound 16 which exhibited effective COX-2 inhibitory activity, with IC50 values of 0.409 µM and an excellent selectivity versus COX-1. Radiolabeling of this most potent derivative [18F]16 was achieved after boron ester release and the tracer was evaluated in vivo in a rat model of neuroinflammation. All chemistry, radiochemistry and biological experimental data are discussed.
Collapse
Affiliation(s)
- Jonathan Elie
- a ICOA, UMR CNRS 7311 , University of Orleans , Orleans , France.,b UMR 1253, iBrain , Université de Tours, Inserm , Tours , France
| | - Johnny Vercouillie
- b UMR 1253, iBrain , Université de Tours, Inserm , Tours , France.,c CERRP , Centre d'Etude et de Recherche sur les Radiopharmaceutiques , Tours , France.,d CHRU , de Tours , Tours , France.,e INSERM CIC 1415 , University of François-Rabelais de Tours , Tours , France
| | - Nicolas Arlicot
- b UMR 1253, iBrain , Université de Tours, Inserm , Tours , France.,c CERRP , Centre d'Etude et de Recherche sur les Radiopharmaceutiques , Tours , France.,d CHRU , de Tours , Tours , France.,e INSERM CIC 1415 , University of François-Rabelais de Tours , Tours , France
| | - Lucas Lemaire
- a ICOA, UMR CNRS 7311 , University of Orleans , Orleans , France
| | - Rudy Bidault
- b UMR 1253, iBrain , Université de Tours, Inserm , Tours , France
| | - Sylvie Bodard
- b UMR 1253, iBrain , Université de Tours, Inserm , Tours , France
| | - Christel Hosselet
- b UMR 1253, iBrain , Université de Tours, Inserm , Tours , France.,c CERRP , Centre d'Etude et de Recherche sur les Radiopharmaceutiques , Tours , France
| | - Jean-Bernard Deloye
- c CERRP , Centre d'Etude et de Recherche sur les Radiopharmaceutiques , Tours , France.,f Biopôle Clermont-Limagne , Laboratoires Cyclopharma , Saint-Beauzire , France
| | - Sylvie Chalon
- b UMR 1253, iBrain , Université de Tours, Inserm , Tours , France
| | - Patrick Emond
- b UMR 1253, iBrain , Université de Tours, Inserm , Tours , France
| | - Denis Guilloteau
- b UMR 1253, iBrain , Université de Tours, Inserm , Tours , France.,c CERRP , Centre d'Etude et de Recherche sur les Radiopharmaceutiques , Tours , France.,d CHRU , de Tours , Tours , France.,e INSERM CIC 1415 , University of François-Rabelais de Tours , Tours , France
| | - Frédéric Buron
- a ICOA, UMR CNRS 7311 , University of Orleans , Orleans , France
| | - Sylvain Routier
- a ICOA, UMR CNRS 7311 , University of Orleans , Orleans , France
| |
Collapse
|
10
|
Dupont AC, Largeau B, Guilloteau D, Santiago Ribeiro MJ, Arlicot N. The Place of PET to Assess New Therapeutic Effectiveness in Neurodegenerative Diseases. Contrast Media Mol Imaging 2018; 2018:7043578. [PMID: 29887768 PMCID: PMC5985069 DOI: 10.1155/2018/7043578] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Subscribe] [Scholar Register] [Received: 12/29/2017] [Accepted: 04/01/2018] [Indexed: 12/16/2022]
Abstract
In vivo exploration of neurodegenerative diseases by positron emission tomography (PET) imaging has matured over the last 20 years, using dedicated radiopharmaceuticals targeting cellular metabolism, neurotransmission, neuroinflammation, or abnormal protein aggregates (beta-amyloid and intracellular microtubule inclusions containing hyperphosphorylated tau). The ability of PET to characterize biological processes at the cellular and molecular levels enables early detection and identification of molecular mechanisms associated with disease progression, by providing accurate, reliable, and longitudinally reproducible quantitative biomarkers. Thus, PET imaging has become a relevant imaging method for monitoring response to therapy, approved as an outcome measure in bioclinical trials. The aim of this paper is to review and discuss the current inputs of PET in the assessment of therapeutic effectiveness in neurodegenerative diseases connected by common pathophysiological mechanisms, including Parkinson's disease, Huntington's disease, dementia, amyotrophic lateral sclerosis, multiple sclerosis, and also in psychiatric disorders. We also discuss opportunities for PET imaging to drive more personalized neuroprotective and therapeutic strategies, taking into account individual variability, within the growing framework of precision medicine.
Collapse
Affiliation(s)
- Anne-Claire Dupont
- UMR 1253, iBrain, Université de Tours, Inserm, Tours, France
- CHRU de Tours, Unité de Radiopharmacie, Tours, France
| | | | - Denis Guilloteau
- UMR 1253, iBrain, Université de Tours, Inserm, Tours, France
- CHRU de Tours, Service de Médecine Nucléaire in vitro, Tours, France
- INSERM CIC 1415, University Hospital, Tours, France
| | - Maria Joao Santiago Ribeiro
- UMR 1253, iBrain, Université de Tours, Inserm, Tours, France
- INSERM CIC 1415, University Hospital, Tours, France
- CHRU de Tours, Service de Médecine Nucléaire in vivo, Tours, France
| | - Nicolas Arlicot
- UMR 1253, iBrain, Université de Tours, Inserm, Tours, France
- CHRU de Tours, Unité de Radiopharmacie, Tours, France
- INSERM CIC 1415, University Hospital, Tours, France
| |
Collapse
|
11
|
Genne P, Berthet C, Raguin O, Chalon S, Tizon X, Serriere S, Provent P, Boisferon MHD, Vercouillie J, Mothes C, Gourand F, BARRE L, Guilloteau D, Blom P, Hoflack J. Abstract 1875A: Preclinical proof of concept for the first Nanocyclix TKI-PET radiotracer targeting activated EGFR positive lung tumors. Tumour Biol 2017. [DOI: 10.1158/1538-7445.am2017-1875a] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
|
12
|
Bruno C, Dufour-Rainfray D, Patin F, Vourc'h P, Guilloteau D, Maillot F, Labarthe F, Tardieu M, Andres C, Emond P, Blasco H. Erratum to “Validation of amino-acids measurement in dried blood spot by FIA-MS/MS for PKU management” [Clin. Biochem. 49 (2016) 1047–1050]. Clin Biochem 2017; 50:546. [DOI: 10.1016/j.clinbiochem.2017.03.023] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
13
|
Tronel C, Largeau B, Santiago Ribeiro MJ, Guilloteau D, Dupont AC, Arlicot N. Molecular Targets for PET Imaging of Activated Microglia: The Current Situation and Future Expectations. Int J Mol Sci 2017; 18:ijms18040802. [PMID: 28398245 PMCID: PMC5412386 DOI: 10.3390/ijms18040802] [Citation(s) in RCA: 88] [Impact Index Per Article: 12.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/31/2017] [Revised: 03/15/2017] [Accepted: 03/28/2017] [Indexed: 12/13/2022] Open
Abstract
Microglia, as cellular mediators of neuroinflammation, are implicated in the pathogenesis of a wide range of neurodegenerative diseases. Positron emission tomography (PET) imaging of microglia has matured over the last 20 years, through the development of radiopharmaceuticals targeting several molecular biomarkers of microglial activation and, among these, mainly the translocator protein-18 kDa (TSPO). Nevertheless, current limitations of TSPO as a PET microglial biomarker exist, such as low brain density, even in a neurodegenerative setting, expression by other cells than the microglia (astrocytes, peripheral macrophages in the case of blood brain barrier breakdown), genetic polymorphism, inducing a variation for most of TSPO PET radiopharmaceuticals’ binding affinity, or similar expression in activated microglia regardless of its polarization (pro- or anti-inflammatory state), and these limitations narrow its potential interest. We overview alternative molecular targets, for which dedicated radiopharmaceuticals have been proposed, including receptors (purinergic receptors P2X7, cannabinoid receptors, α7 and α4β2 nicotinic acetylcholine receptors, adenosine 2A receptor, folate receptor β) and enzymes (cyclooxygenase, nitric oxide synthase, matrix metalloproteinase, β-glucuronidase, and enzymes of the kynurenine pathway), with a particular focus on their respective contribution for the understanding of microglial involvement in neurodegenerative diseases. We discuss opportunities for these potential molecular targets for PET imaging regarding their selectivity for microglia expression and polarization, in relation to the mechanisms by which microglia actively participate in both toxic and neuroprotective actions in brain diseases, and then take into account current clinicians’ expectations.
Collapse
Affiliation(s)
- Claire Tronel
- INSERM U930, Université François Rabelais de Tours, 10 boulevard Tonnelé, 37032 Tours, France.
| | | | - Maria Joao Santiago Ribeiro
- INSERM U930, Université François Rabelais de Tours, 10 boulevard Tonnelé, 37032 Tours, France.
- CHRU de Tours, 37044 Tours, France.
| | - Denis Guilloteau
- INSERM U930, Université François Rabelais de Tours, 10 boulevard Tonnelé, 37032 Tours, France.
- CHRU de Tours, 37044 Tours, France.
| | - Anne-Claire Dupont
- INSERM U930, Université François Rabelais de Tours, 10 boulevard Tonnelé, 37032 Tours, France.
- CHRU de Tours, 37044 Tours, France.
| | - Nicolas Arlicot
- INSERM U930, Université François Rabelais de Tours, 10 boulevard Tonnelé, 37032 Tours, France.
- CHRU de Tours, 37044 Tours, France.
| |
Collapse
|
14
|
Dupont AC, Largeau B, Santiago Ribeiro MJ, Guilloteau D, Tronel C, Arlicot N. Translocator Protein-18 kDa (TSPO) Positron Emission Tomography (PET) Imaging and Its Clinical Impact in Neurodegenerative Diseases. Int J Mol Sci 2017; 18:ijms18040785. [PMID: 28387722 PMCID: PMC5412369 DOI: 10.3390/ijms18040785] [Citation(s) in RCA: 119] [Impact Index Per Article: 17.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/31/2017] [Revised: 03/31/2017] [Accepted: 04/04/2017] [Indexed: 02/06/2023] Open
Abstract
In vivo exploration of activated microglia in neurodegenerative diseases is achievable by Positron Emission Tomography (PET) imaging, using dedicated radiopharmaceuticals targeting the translocator protein-18 kDa (TSPO). In this review, we emphasized the major advances made over the last 20 years, thanks to TSPO PET imaging, to define the pathophysiological implication of microglia activation and neuroinflammation in neurodegenerative diseases, including Parkinson’s disease, Huntington’s disease, dementia, amyotrophic lateral sclerosis, multiple sclerosis, and also in psychiatric disorders. The extent and upregulation of TSPO as a molecular biomarker of activated microglia in the human brain is now widely documented in these pathologies, but its significance, and especially its protective or deleterious action regarding the disease’s stage, remains under debate. Thus, we exposed new and plausible suggestions to enhance the contribution of TSPO PET imaging for biomedical research by exploring microglia’s role and interactions with other cells in brain parenchyma. Multiplex approaches, associating TSPO PET radiopharmaceuticals with other biomarkers (PET imaging of cellular metabolism, neurotransmission or abnormal protein aggregates, but also other imaging modalities, and peripheral cytokine levels measurement and/or metabolomics analysis) was considered. Finally, the actual clinical impact of TSPO PET imaging as a routine biomarker of neuroinflammation was put into perspective regarding the current development of diagnostic and therapeutic strategies for neurodegenerative diseases.
Collapse
Affiliation(s)
- Anne-Claire Dupont
- CHRU Tours, 2 Boulevard Tonnellé, 37044 Tours, France.
- Institut National de la Santé et de la Recherche Médicale U930, 10 Boulevard Tonnellé, 37032 Tours, France.
| | | | - Maria Joao Santiago Ribeiro
- CHRU Tours, 2 Boulevard Tonnellé, 37044 Tours, France.
- Institut National de la Santé et de la Recherche Médicale U930, 10 Boulevard Tonnellé, 37032 Tours, France.
| | - Denis Guilloteau
- CHRU Tours, 2 Boulevard Tonnellé, 37044 Tours, France.
- Institut National de la Santé et de la Recherche Médicale U930, 10 Boulevard Tonnellé, 37032 Tours, France.
| | - Claire Tronel
- Institut National de la Santé et de la Recherche Médicale U930, 10 Boulevard Tonnellé, 37032 Tours, France.
| | - Nicolas Arlicot
- CHRU Tours, 2 Boulevard Tonnellé, 37044 Tours, France.
- Institut National de la Santé et de la Recherche Médicale U930, 10 Boulevard Tonnellé, 37032 Tours, France.
| |
Collapse
|
15
|
Dupont AC, Santiago Ribeiro MJ, Guilloteau D, Arlicot N. β-amyloid PET neuroimaging: A review of radiopharmaceutical development. Médecine Nucléaire 2017. [DOI: 10.1016/j.mednuc.2016.12.002] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/29/2023]
|
16
|
Barbet J, Arlicot N, Gaugler MH, Chérel M, Guilloteau D, Kraeber-Bodéré F. Editorial: Innovative Radiopharmaceuticals in Oncology and Neurology. Front Med (Lausanne) 2017; 3:74. [PMID: 28123998 PMCID: PMC5225142 DOI: 10.3389/fmed.2016.00074] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/09/2016] [Accepted: 12/21/2016] [Indexed: 11/13/2022] Open
Affiliation(s)
- Jacques Barbet
- Centre Régional de Recherche en Cancérologie Nantes/Angers (CRCNA), UMR892 Inserm, Nantes, France; 6299 CNRS, Nantes, France; Université de Nantes, Nantes, France; GIP Arronax, Saint-Herblain, France
| | - Nicolas Arlicot
- UMR Inserm U930, Tours, France; Université François Rabelais, Tours, France; CHRU de Tours, Hôpital Bretonneau, Tours, France
| | - Marie-Hélène Gaugler
- Centre Régional de Recherche en Cancérologie Nantes/Angers (CRCNA), UMR892 Inserm, Nantes, France; 6299 CNRS, Nantes, France; Université de Nantes, Nantes, France
| | - Michel Chérel
- Centre Régional de Recherche en Cancérologie Nantes/Angers (CRCNA), UMR892 Inserm, Nantes, France; 6299 CNRS, Nantes, France; Université de Nantes, Nantes, France; Service de Médecine Nucléaire, Institut de Cancérologie de l'Ouest, Saint-Herblain, France
| | - Denis Guilloteau
- UMR Inserm U930, Tours, France; Université François Rabelais, Tours, France; CHRU de Tours, Hôpital Bretonneau, Tours, France
| | - Françoise Kraeber-Bodéré
- Centre Régional de Recherche en Cancérologie Nantes/Angers (CRCNA), UMR892 Inserm, Nantes, France; 6299 CNRS, Nantes, France; Université de Nantes, Nantes, France; Service de Médecine Nucléaire, Institut de Cancérologie de l'Ouest, Saint-Herblain, France; Service de Médecine Nucléaire, CHU de Nantes, Nantes, France
| |
Collapse
|
17
|
Feng L, Jensen P, Thomsen G, Dyssegaard A, Svarer C, Knudsen LV, Møller K, Thomsen C, Mikkelsen JD, Guilloteau D, Knudsen GM, Pinborg LH. The Variability of Translocator Protein Signal in Brain and Blood of Genotyped Healthy Humans Using In Vivo 123I-CLINDE SPECT Imaging: A Test–Retest Study. J Nucl Med 2016; 58:989-995. [DOI: 10.2967/jnumed.116.183202] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/27/2016] [Accepted: 10/21/2016] [Indexed: 11/16/2022] Open
|
18
|
Perrotin A, La Joie R, de La Sayette V, Barré L, Mézenge F, Mutlu J, Guilloteau D, Egret S, Eustache F, Chételat G. Subjective cognitive decline in cognitively normal elders from the community or from a memory clinic: Differential affective and imaging correlates. Alzheimers Dement 2016; 13:550-560. [PMID: 27693187 DOI: 10.1016/j.jalz.2016.08.011] [Citation(s) in RCA: 120] [Impact Index Per Article: 15.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/07/2016] [Revised: 08/05/2016] [Accepted: 08/17/2016] [Indexed: 01/21/2023]
Abstract
INTRODUCTION Subjective cognitive decline (SCD) could indicate preclinical Alzheimer's disease, but the existing literature is confounded by heterogeneous approaches to studying SCD. We assessed the differential cognitive, affective, and neuroimaging correlates of two aspects of SCD: reporting high cognitive difficulties on a self-rated questionnaire versus consulting at a memory clinic. METHODS We compared 28 patients from a memory clinic with isolated SCD, 35 community-recruited elders with similarly high levels of self-reported cognitive difficulties, and 35 community-recruited controls with low self-reported cognitive difficulties. RESULTS Increased anxiety and amyloid β deposition were observed in both groups with high self-reported difficulties, whereas subclinical depression and (hippocampal) atrophy were specifically associated with medical help seeking. Cognitive tests showed no group differences. DISCUSSION These results further validate the concept of SCD in both community- and clinic-based groups. Yet, recruitment methods influence associated biomarkers and affective symptomatology, highlighting the heterogeneous nature of SCD depending on study characteristics.
Collapse
Affiliation(s)
- Audrey Perrotin
- INSERM, U1077, Caen, France; Université de Caen Normandie, UMR-S1077, Caen, France; Ecole Pratique des Hautes Etudes, UMR-S1077, Caen, France; CHU de Caen, U1077, Caen, France
| | - Renaud La Joie
- INSERM, U1077, Caen, France; Université de Caen Normandie, UMR-S1077, Caen, France; Ecole Pratique des Hautes Etudes, UMR-S1077, Caen, France; CHU de Caen, U1077, Caen, France.
| | - Vincent de La Sayette
- INSERM, U1077, Caen, France; Université de Caen Normandie, UMR-S1077, Caen, France; Ecole Pratique des Hautes Etudes, UMR-S1077, Caen, France; CHU de Caen, Service de Neurologie, Caen, France
| | - Louisa Barré
- Université de Caen Normandie, UMR-S1077, Caen, France; CEA, DRF/I2BM, LDM-TEP Group, Caen, France; CNRS, UMR ISTCT 6301, LDM-TEP Group, Caen, France
| | - Florence Mézenge
- INSERM, U1077, Caen, France; Université de Caen Normandie, UMR-S1077, Caen, France; Ecole Pratique des Hautes Etudes, UMR-S1077, Caen, France; CHU de Caen, U1077, Caen, France
| | - Justine Mutlu
- INSERM, U1077, Caen, France; Université de Caen Normandie, UMR-S1077, Caen, France; Ecole Pratique des Hautes Etudes, UMR-S1077, Caen, France; CHU de Caen, U1077, Caen, France
| | - Denis Guilloteau
- INSERM U930, Université François Rabelais de Tours, CHRU de Tours, Tours, France
| | - Stéphanie Egret
- INSERM, U1077, Caen, France; Université de Caen Normandie, UMR-S1077, Caen, France; Ecole Pratique des Hautes Etudes, UMR-S1077, Caen, France; CHU de Caen, U1077, Caen, France
| | - Francis Eustache
- INSERM, U1077, Caen, France; Université de Caen Normandie, UMR-S1077, Caen, France; Ecole Pratique des Hautes Etudes, UMR-S1077, Caen, France; CHU de Caen, U1077, Caen, France
| | - Gaël Chételat
- INSERM, U1077, Caen, France; Université de Caen Normandie, UMR-S1077, Caen, France; Ecole Pratique des Hautes Etudes, UMR-S1077, Caen, France; CHU de Caen, U1077, Caen, France
| |
Collapse
|
19
|
Rodrigues N, Boiaryna L, Vercouillie J, Guilloteau D, Suzenet F, Buron F, Routier S. Tandem Silver-Catalyzed Cyclization/Nucleophilic Functionalization of 2-Alkynylindole-3-carbaldehyde Oximes to Afford New 2,4-Disubstituted γ-Carbolines. European J Org Chem 2016. [DOI: 10.1002/ejoc.201600904] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/01/2023]
Affiliation(s)
| | | | - Johnny Vercouillie
- UMR Inserm U930; Université François Rabelais de Tours, CHRU de Tours; Tours France
| | - Denis Guilloteau
- UMR Inserm U930; Université François Rabelais de Tours, CHRU de Tours; Tours France
| | | | | | | |
Collapse
|
20
|
Zimmer L, Breton P, Durand G, Guilloteau D, Besnard J, Chalon S. Prominent Role ofn—3 Polyunsaturated Fatty Acids in Cortical Dopamine Metabolism. Nutr Neurosci 2016; 2:257-65. [DOI: 10.1080/1028415x.1999.11747282] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
21
|
Radchenko V, Engle JW, Roy C, Griswold J, Nortier MF, Birnbaum ER, Brugh M, Mirzadeh S, John KD, Fassbender ME, Zhai C, Franssen GM, Petrik M, Laverman P, Decristoforo C, Samia AM, Véronique DP, Brigitte G, Summer D, Kroess A, Rangger C, Haas H, Laverman P, Gerben F, von Guggenberg E, Decristoforo C, Bolzati C, Salvarese N, Refosco F, Meléndez-Alafort L, Carpanese D, Rosato A, Saviano M, Del Gatto A, Comegna D, Zaccaro L, Billaud E, Ahamed M, Cleeren F, Shahbazali E, Noël T, Hessel V, Verbruggen A, Bormans G, Cleeren F, Lecina J, Koole M, Verbruggen A, Bormans G, Lugatoa B, Stucchia S, Turollaa EA, Giulianoa L, Toddea S, Ferraboschib P, Klok RP, Mooijer MPJ, Hendrikse NH, Windhorst AD, Collet C, Petry N, Chrétien F, Karcher G, Pellegrini-Moïse N, Lamandé-Langle S, Pfaff S, Philippe C, Mitterhauser M, Hacker M, Wadsak W, Guérard F, Lee YS, Gouard S, Baidoo K, Alliot C, Chérel M, Brechbiel MW, Gestin JF, Lam K, Chan C, Reilly RM, Paillas S, Marshall J, Pouget JP, Sosabowski J, Briard E, Auberson YP, Reilly J, Healy M, Sykes D, Paulus A, Lichtenbelt WVM, Mottaghy F, Bauwens M, Baranski AC, Schäfer M, Bauder-Wüst U, Haberkorn U, Eder M, Kopka K, Chaussard M, Hosten B, Vignal N, Tsoupko-Sitnikov V, Hernio N, Hontonnou F, Merlet P, Poyet JL, Sarda-Mantel L, Rizzo-Padoin N, Cardinale J, Schäfer M, Benešová M, Bauder-Wüst U, Seibert O, Giesel F, Haberkorn U, Eder M, Kopka K, Nematallah M, Michel P, Samia AM, Véronique DP, Roger L, Brigitte G, Fernandez-Maza L, Rivera-Marrero S, Capote AP, Parrado-Gallego A, Fernandez-Gomez I, Balcerzyk M, Sablon-Carrazana M, Perera-Pintado A, Merceron-Martinez D, Acosta-Medina E, Rodriguez-Tanty C, Attili B, Ahamed M, Bormans G, Philippe C, Zeilinger M, Scherer T, Fürnsinn C, Dumanic M, Wadsak W, Hacker M, Mitterhauser M, Janssen B, Vugts DJ, Molenaar GT, Funke U, Kruijer PS, Dollé F, Bormans G, Lammertsma AA, Windhorst AD, Vermeulen K, Ahamed M, Schnekenburger M, Froeyen M, Olberg DE, Diederich M, Bormansa G, Raaphorst RM, Luurtsema G, Lammertsma AA, Elsinga PH, Windhorst AD, Rotteveel L, Funke U, ten Dijke P, Bogaard HJ, Lammertsma AA, Windhorst AD, Song L, Able S, Falzone N, Kersemans V, Vallis K, Carta D, Salvarese N, Sihver W, Gao F, Pietzsch HJ, Biondi B, Ruzza P, Refosco F, Bolzati C, Haubner R, Finkensted A, Stegmair A, Rangger C, Decristoforo C, Zoller H, Virgolini IJ, Pooters I, Lotz M, Wierts R, Mottaghy F, Bauwens M, Forsback S, Jörgen B, Riikka K, Karageorgou M, Radović M, Tsoukalas C, Antic B, Gazouli M, Paravatou-Petsotas M, Xanthopouls S, Calamiotou M, Stamopoulos D, Vranješ-Durić S, Bouziotis P, Lunev AS, Larenkov AA, Petrosova KA, Klementyeva OE, Kodina GE, Kvernenes OH, Adamsen TCH, Martin R, Weidlich S, Zerges AM, Gameiro C, Lazarova N, Müllera M, Luurtsema G, de Vries M, Ghyoot M, van der Woude G, Zijlma R, Dierckx R, Boersma HH, Elsinga PH, Lambrecht FY, Er O, Ince M, Avci CB, Gunduz C, Sarı FA, Ocakoglu K, Er O, Ersoz OA, Lambrecht FY, Ince M, Kayabasi C, Gunduz C, Kniess T, Meister S, Fischer S, Steinbach J, Ashfaq R, Iqbal S, ullah Khan I, Iglesias-Jerez R, Martín-Banderas L, Perera-Pintado A, Borrego-Dorado I, Farinha-Antunes I, Kwizera C, Lacivita E, Lucente E, Niso M, De Giorgio P, Perrone R, Colabufo NA, Elsinga PH, Leopoldo M, Vaulina VV, Fedorova OS, Orlovskaja VV, Chen СL, Li GY, Meng FC, Liu RS, Wang HE, Krasikova RN, Meléndez-Alafort L, Abozeid M, Ferro-Flores G, Negri A, Bello M, Uzunov N, Paiusco M, Esposito J, Rosato A, Meléndez-Alafort L, Bolzati C, Ferro-Flores G, Salvarese N, Carpanese D, Abozeid M, Rosato A, Uzunov N, Palmieri L, Verbrugghen T, Glassner M, Hoogenboom R, Staelens S, Wyffels L, Orlovskaja VV, Kuznetsova OF, Fedorova OS, Maleev VI, Belokon YN, Geolchanyan A, Saghyan AS, Mu L, Schibli R, Ametamey SM, Krasikova RN, Revunov E, Malmquist J, Johnström P, Van Valkenburgh J, Steele D, Halldin C, Schou M, Osati S, Paquette M, Beaudoin S, Ali H, Guerin B, Leyton JV, van Lier JE, Di Iorio V, Iori M, Donati C, Lanzetta V, Capponi PC, Rubagotti S, Dreger T, Kunkel F, Asti M, Zhai C, Rangger C, Summer D, Haas H, Decristoforo C, Kijprayoon S, Ruangma A, Ngokpol S, Tuamputsha S, Filp U, Pees A, Taddei C, Pekošak A, Gee AD, Poot AJ, Windhorst AD, Gunay MS, Ozer AY, Erdogan S, Baysal I, Guilloteau D, Chalon S, Galli F, Artico M, Taurone S, Bianchi E, Weintraub BD, Skudlinski M, Signore A, Lepareur N, Noiret N, Hindré F, Lacœuille F, Benoist E, Garin E, Trejo-Ballado F, Zamora-Romo E, Manrique-Arias JC, Gama-Romero HM, Contreras-Castañon G, Tecuapetla-Chantes RG, Avila-Rodriguez MA, Kvaternik H, Hausberger D, Zink C, Rumpf B, Aigner RM, Kvaternik H, Hausberger D, Rumpf B, Aigner RM, Janković D, Lakić M, Savić A, Ristić S, Nikolić N, Vukadinović A, Sabo TJ, Vranješ-Đurić S, Vranješ-Đurić S, Radović M, Janković D, Nikolić N, Goya GF, Calatayud P, Spasojević V, Antić B, Goblet D, Gameiro C, Lazarova N, Gameiro C, Oxley I, Abrunhosa A, Kramer V, Vosjan M, Spaans A, Vats K, Satpati D, Sarma HD, Banerjee S, Wojdowska W, Pawlak DW, Parus LJ, Garnuszek P, Mikołajczak R, Pijarowska-Kruszyna J, Jaron A, Kachniarz A, Malkowski B, Garnuszek P, Mikolajczak R, Ilem-Ozdemir D, Caglayan-Orumlu O, Asikoglu M, Ilem-Ozdemir D, Caglayan-Orumlu O, Asikoglu M, Eveliina A, Semi H, Timo S, Simo V, Esa K, Pertti L, De Simone M, Pascali G, Carzoli L, Quaglierini M, Telleschi M, Salvadori PA, Lam P, Aistleitner M, Eichinger R, Artner C, Nakka S, MC HK, Al-Qahtani M, Al-Qahtani M, Al-Malki Y, Mambilima N, Rubow SM, Berroterán-Infante N, Hacker M, Mitterhauser M, Wadsak W, Funke U, Cleeren F, Lecina J, Gallardo R, Verbruggen AM, Bormans G, Ramos-Membrive R, Brotons A, Quincoces G, Inchaurraga L, de Redín IL, Morán V, García-García B, Irache JM, Peñuelas I, Trabelsi M, Cooper MS, Abella A, Fuente T, Montellano AJ, Martínez T, Rabadan R, Meseguer-Olmo L, Lehtiniemi P, Yim C, Mikkola K, Nuutila P, Solin O, von Guggenberg E, Rangger C, Mair C, Balogh L, Pöstényi Z, Pawlak D, Mikołajczak R, Socan A, Peitl PK, Krošelj M, Rangger C, Decristoforo C, Collet C, Remy S, Didier R, Vergote T, Karcher G, Véran N, Pawlak D, Maurin M, Garnuszek P, Karczmarczyk U, Mikołajczak R, Fredericia P, Severin G, Groesser T, Köster U, Jensen M, Leonte R, Puicea FD, Raicu A, Min EA, Serban R, Manda G, Niculae D, Zerna M, Schieferstein H, Müller A, Berndt M, Yim CB, Mikkola K, Nuutila P, Solin O, Seifert D, Ráliš J, Lebeda O, Selivanova SV, Senta H, Lavallée É, Caouette L, Turcotte É, Lecomte R, Kochovska MZ, Ivanovska EJ, Jokic VS, Ackova DG, Smilkov K, Makreski P, Stafilov T, Janevik-Ivanovska E, Alemu A, Muchira JM, Wanjeh DM, Janevik-Ivanovska E, Janevik-Ivanovska E, Zdravev Z, Bhonsle U, Alberto OJJ, Duatti A, Angelovska B, Stojanovska Z, Sarafinovska ZA, Bosnakovski D, Gorgieva-Ackova D, Smilkov K, Drakalska E, Venkatesh M, Gulaboski R, Colin DJ, Inkster JAH, Germain S, Seimbille Y. 18th European Symposium on Radiopharmacy and Radiopharmaceuticals. EJNMMI Radiopharm Chem 2016. [PMCID: PMC5843810 DOI: 10.1186/s41181-016-0012-6] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open
Abstract
OP03 Selective extraction of medically-related radionuclides from proton-irradiated thorium targets V. Radchenko, J.W. Engle, C. Roy, J. Griswold, M.F. Nortier, E.R. Birnbaum, M. Brugh, S. Mirzadeh, K. D. John, M.E. Fassbender OP04 Comparison of [68Ga]FSC(succ-RGD)3 and [68Ga]NODAGA-RGD for PET imaging of αvβ3 integrin expression Chuangyan Zhai, Gerben M. Franssen, Milos Petrik, Peter Laverman, Clemens Decristoforo OP05 A new NPY-Y1R targeting peptide for breast cancer PET imaging Ait-Mohand Samia, Dumulon-Perreault Véronique, Guérin Brigitte OP06 The influence of multivalency on CCK 2 receptor targeting D. Summer, A. Kroess, C. Rangger, H. Haas, P. Laverman, F. Gerben, E. von Guggenberg, C.Decristoforo OP07 SPECT Imaging of αvβ3 Expression by [99mTc(N)PNP43]- Bifunctional Chimeric RGD Peptide not Cross-Reacting with αvβ5 Cristina Bolzati, Nicola Salvarese, Fiorenzo Refosco, Laura Meléndez-Alafort, Debora Carpanese, Antonio Rosato, Michele Saviano, Annarita Del Gatto, Daniela Comegna, Laura Zaccaro OP09 New dienophiles for the inverse-electron-demand Diels-Alder reaction and for pretargeted PET imaging Emilie Billaud, Muneer Ahamed, Frederik Cleeren, Elnaz Shahbazali, Tim Noël, Volker Hessel, Alfons Verbruggen and Guy Bormans OP10 New complexing agent for Al18F-labelling of heat-sensitive biomolecules: Synthesis and preclinical evaluation of Al18F-RESCA1-HAS Cleeren F, Lecina J, Koole M, Verbruggen A and Bormans G OP11 A novel versatile precursor efficient for F-18 radiolabelling via click-chemistry B. Lugatoa, S. Stucchia, E.A. Turollaa, L. Giulianoa, S.Toddea, P. Ferraboschib OP12 A general applicable method to quantify unidentified UV impurities in radiopharmaceuticals R.P. Klok, M.P.J. Mooijer, N.H. Hendrikse, A.D. Windhorst OP13 Development of [18F]Fluoro-C-glycosides to radiolabel peptides Collet C., Petry N., Chrétien F., Karcher G., Pellegrini-Moïse N., Lamandé-Langle S. OP14 A Microfluidic Approach for the 68Ga-labeling of PSMAHBED-CC and NODAGA-RGD Sarah Pfaff, Cecile Philippe, Markus Mitterhauser, Marcus Hacker, Wolfgang Wadsak OP16 Surprising reactivity of astatine in the nucleophilic substitution of aryliodonium salts: application to the radiolabeling of antibodies François Guérard, Yong-Sok Lee, Sébastien Gouard, Kwamena Baidoo, Cyrille Alliot, Michel Chérel, Martin W. Brechbiel, Jean-François Gestin OP17 64Cu-NOTA-pertuzumab F(ab')2 fragments, a second-generation probe for PET imaging of the response of HER2-positive breast cancer to trastuzumab (Herceptin) Lam K, Chan C, Reilly RM OP18 Development of radiohalogenated analogues of a avb6-specific peptide for high LET particle emitter targeted radionuclide therapy of cancer Salomé Paillas, John Marshall, Jean-Pierre Pouget, Jane Sosabowski OP19 Ligand Specific Efficiency (LSE) as a guide in tracer optimization Emmanuelle Briard, Yves P. Auberson, John Reilly, Mark Healy, David Sykes OP23 The radiosynthesis of an 18F-labeled triglyceride, developed to visualize and quantify brown adipose tissue activity Andreas Paulus, Wouter van Marken Lichtenbelt,Felix Mottaghy, Matthias Bauwens OP24 Influence of the fluorescent dye on the tumor targeting properties of dual-labeled HBED-CC based PSMA inhibitors Baranski, Ann-Christin, Schäfer, Martin, Bauder-Wüst, Ulrike, Haberkorn, Uwe, Eder, Matthias, Kopka, Klaus OP25 [18F]MEL050 as a melanin PET tracer : fully automated radiosynthesis and evaluation for the detection of pigmented melanoma in mice pulmonary metastases Chaussard M, Hosten B, Vignal N, Tsoupko-Sitnikov V, Hernio N, Hontonnou F, Merlet P, Poyet JL, Sarda-Mantel L, Rizzo-Padoin N OP26 Design and Preclinical Evaluation of Novel Radiofluorinated PSMA Targeting Ligands Based on PSMA-617 J. Cardinale, M. Schäfer, M. Benešová, U. Bauder-Wüst, O. Seibert, F. Giesel, U. Haberkorn, M. Eder, K. Kopka OP27 A novel radiolabeled peptide for PET imaging of prostate cancer: 64Cu-DOTHA2-PEG-RM26 Mansour Nematallah, Paquette Michel, Ait-Mohand Samia, Dumulon-Perreault Véronique, Lecomte Roger, Guérin Brigitte OP29 Biodistribution of [18F]Amylovis®, a new radiotracer PET imaging of β-amyloid plaques Fernandez-Maza L, Rivera-Marrero S, Prats Capote A, Parrado-Gallego A, Fernandez-Gomez I, Balcerzyk M, Sablon-Carrazana M, Perera-Pintado A, Merceron-Martinez D, Acosta-Medina E, Rodriguez-Tanty C OP30 Synthesis and preclinical evaluation of [11C]-BA1 PET tracer for the imaging of CSF-1R Bala Attili, Muneer Ahamed, Guy Bormans OP31 In vivo imaging of the MCHR1 in the ventricular system via [18F]FE@SNAP C. Philippe, M. Zeilinger, T. Scherer, C. Fürnsinn, M. Dumanic, W. Wadsak, M. Hacker, M. Mitterhauser OP32 Synthesis of the first carbon-11 labelled P2Y12 receptor antagonist for imaging the anti-inflammatory phenotype of activated microglia B. Janssen, D.J. Vugts, G.T. Molenaar, U. Funke, P.S. Kruijer, F. Dollé, G. Bormans, A.A. Lammertsma, A.D. Windhorst OP33 Radiosynthesis of a selective HDAC6 inhibitor [11C]KB631 and in vitro and ex vivo evaluation Koen Vermeulen, Muneer Ahamed, Michael Schnekenburger, Mathy Froeyen, Dag Erlend Olberg, Marc Diederich, Guy Bormansa OP34 Improving metabolic stability of fluorine-18 labelled verapamil analogues Raaphorst RM, Luurtsema G, Lammertsma AA, Elsinga PH, Windhorst AD OP36 Development of a novel PET tracer for the activin receptor-like kinase 5 Lonneke Rotteveel, Uta Funke, Peter ten Dijke, Harm Jan Bogaard, Adriaan A. Lammertsma, Albert D. Windhorst OP37 SPECT imaging and biodistribution studies of 111In-EGF-Au-PEG nanoparticles in vivo Lei Song, Sarah Able, Nadia Falzone, Veerle Kersemans, Katherine Vallis OP38 Melanoma targeting with [99mTc(N)(PNP3)]-labeled NAPamide derivatives: preliminary pharmacological studies Davide Carta, Nicola Salvarese, Wiebke Sihver, Feng Gao, Hans Jürgen Pietzsch, Barbara Biondi, Paolo Ruzza, Fiorenzo Refosco, Cristina Bolzati OP39 [68Ga]NODAGA-RGD: cGMP synthesis and data from a phase I clinical study Roland Haubner, Armin Finkensted, Armin Stegmair, Christine Rangger, Clemens Decristoforo, Heinz Zoller, Irene J. Virgolin OP44 Implementation of a GMP-grade radiopharmacy facility in Maastricht Ivo Pooters, Maartje Lotz, Roel Wierts, Felix Mottaghy, Matthias Bauwens OP45 Setting up a GMP production of a new radiopharmaceutical Forsback, Sarita, Bergman Jörgen, Kivelä Riikka OP48 In vitro and in vivo evaluation of 68-gallium labeled Fe3O4-DPD nanoparticles as potential PET/MRI imaging agents M. Karageorgou, M. Radović, C. Tsoukalas, B. Antic, M. Gazouli, M. Paravatou-Petsotas, S. Xanthopouls, M. Calamiotou, D. Stamopoulos, S. Vranješ-Durić, P. Bouziotis OP49 Fast PET imaging of inflammation using 68Ga-citrate with Fe-containing salts of hydroxy acids A. S. Lunev, A. A. Larenkov, K.A. Petrosova, O. E. Klementyeva, G. E. Kodina PP01 Installation and validation of 11C-methionine synthesis Kvernenes, O.H., Adamsen, T.C.H. PP02 Fully automated synthesis of 68Ga-labelled peptides using the IBA Synthera® and Synthera® Extension modules René Martin, Sebastian Weidlich, Anna-Maria Zerges, Cristiana Gameiro, Neva Lazarova, Marco Müllera PP03 GMP compliant production of 15O-labeled water using IBA 18 MeV proton cyclotron Gert Luurtsema, Michèl de Vries, Michel Ghyoot, Gina van der Woude, Rolf Zijlma, Rudi Dierckx, Hendrikus H. Boersma, Philip H. Elsinga PP04 In vitro Nuclear Imaging Potential of New Subphthalocyanine and Zinc Phthalocyanine Fatma Yurt Lambrecht, Ozge Er, Mine Ince, Cıgır Biray Avci, Cumhur Gunduz, Fatma Aslihan Sarı PP05 Synthesis, Photodynamic Therapy Efficacy and Nuclear Imaging Potential of Zinc Phthalocyanines Kasim Ocakoglu, Ozge Er, Onur Alp Ersoz, Fatma Yurt Lambrecht, Mine Ince, Cagla Kayabasi, Cumhur Gunduz PP06 Radio-U(H)PLC – the Search on the Optimal Flow Cell for the γ-Detector Torsten Kniess, Sebastian Meister, Steffen Fischer, Jörg Steinbach PP07 Radiolabeling, characterization & biodistribution study of cysteine and its derivatives with Tc99m Rabia Ashfaq, Saeed Iqbal, Atiq-ur-Rehman, Irfan ullah Khan PP08 Radiolabelling of poly (lactic-co.glycolic acid) (PLGA) nanoparticles with 99mTC R Iglesias-Jerez, Cayero-Otero, L. Martín-Banderas, A. Perera-Pintado, I. Borrego-Dorado PP09 Development of [18F]PD-410 as a non-peptidic PET radiotracer for gastrin releasing peptide receptors Ines Farinha-Antunes, Chantal Kwizera, Enza Lacivita, Ermelinda Lucente, Mauro Niso, Paola De Giorgio, Roberto Perrone, Nicola A. Colabufo, Philip H. Elsinga, Marcello Leopoldo PP10 An improved nucleophilic synthesis of 2-(3,4-dimethoxyphenyl)-6-(2-[18F]fluoroethoxy) benzothiazole ([18F]FEDMBT), potential diagnostic agent for breast cancer imaging by PET V.V. Vaulina, O.S. Fedorova, V.V. Orlovskaja, С.L. Chen, G.Y. Li, F.C. Meng, R.S. Liu, H.E. Wang, R.N. Krasikova PP11 Internal radiation dose assessment of radiopharmaceuticals prepared with accelerator-produced 99mTc Laura Meléndez-Alafort, Mohamed Abozeid, Guillermina Ferro-Flores, Anna Negri, Michele Bello, Nikolay Uzunov, Martha Paiusco, Juan Esposito, Antonio Rosato PP12 A specialized five-compartmental model software for pharmacokinetic parameters calculation Laura Meléndez-Alafort, Cristina Bolzati, Guillermina Ferro-Flores, Nicola Salvarese, Debora Carpanese, Mohamed Abozeid, Antonio Rosato, Nikolay Uzunov PP13 Molecular imaging of the pharmacokinetic behavior of low molecular weight 18F-labeled PEtOx in comparison to 89Zr-labeled PEtOx Palmieri L, Verbrugghen T, Glassner M, Hoogenboom R, Staelens S, Wyffels L PP14 Towards nucleophilic synthesis of the α-[18F]fluoropropyl-L-dihydroxyphenylalanine V. V. Orlovskaja, O. F. Kuznetsova, O. S. Fedorova, V. I. Maleev, Yu. N. Belokon, A. Geolchanyan, A. S. Saghyan, L. Mu, R. Schibli, S. M. Ametamey, R. N. Krasikova PP15 A convenient one-pot synthesis of [18F]clofarabine Revunov, Evgeny, Malmquist, Jonas, Johnström, Peter, Van Valkenburgh, Juno, Steele, Dalton, Halldin, Christer, Schou, Magnus PP16 BODIPY-estradiol conjugates as multi-modality tumor imaging agents Samira Osati,Michel Paquette,Simon Beaudoin,Hasrat Ali,Brigitte Guerin, Jeffrey V. Leyton, Johan E. van Lier PP17 Easy and high yielding synthesis of 68Ga-labelled HBED-PSMA and DOTA-PSMA by using a Modular-Lab Eazy automatic synthesizer Di Iorio V, Iori M, Donati C, Lanzetta V, Capponi PC, Rubagotti S, Dreger T, Kunkel F, Asti M PP18 Synthesis and evaluation of fusarinine C-based octadentate bifunctional chelators for zirconium-89 labelling Chuangyan Zhai, Christine Rangger, Dominik Summer, Hubertus Haas, Clemens Decristoforo PP19 Fully automated production of [18F]NaF using a re-configuring FDG synthesis module. Suphansa Kijprayoon, Ananya Ruangma, Suthatip Ngokpol, Samart Tuamputsha PP20 Extension of the Carbon-11 Small Labeling Agents Toolbox and Conjugate Addition Ulrike Filp, Anna Pees, Carlotta Taddei, Aleksandra Pekošak, Antony D. Gee, Alex J. Poot, Albert D. Windhorst PP21 In vitro studies on BBB penetration of pramipexole encapsulated theranostic liposomes for the therapy of Parkinson’s disease Mine Silindir Gunay, A. Yekta Ozer, Suna Erdogan, Ipek Baysal, Denis Guilloteau, Sylvie Chalon PP22 Factors affecting tumor uptake of 99mTc-HYNIC-VEGF165 Filippo Galli, Marco Artico, Samanta Taurone, Enrica Bianchi, Bruce D. Weintraub, Mariusz Skudlinski, Alberto Signore PP23 Rhenium-188: a suitable radioisotope for targeted radiotherapy Nicolas Lepareur, Nicolas Noiret, François Hindré, Franck Lacœuille, Eric Benoist, Etienne Garin PP24 Preparation of a broad palette of 68Ga radiopharmaceuticals for clinical applications Trejo-Ballado F, Zamora-Romo E, Manrique-Arias JC, Gama-Romero HM, Contreras-Castañon G, Tecuapetla-Chantes RG, Avila-Rodriguez MA PP25 68Ga-peptide preparation with the use of two 68Ge/68Ga-generators H. Kvaternik, D. Hausberger, C. Zink, B. Rumpf, R. M. Aigner PP26 Assay of HEPES in 68Ga-peptides by HPLC H. Kvaternik, D. Hausberger, B. Rumpf, R. M. Aigner PP27 Preparation, in vitro and in vivo evaluation of a 99mTc(I)-Diethyl Ester (S,S)-Ethylenediamine- N,N´-DI-2-(3-Cyclohexyl) Propionic acid as a target-specific radiopharmaceutical Drina Janković, Mladen Lakić, Aleksandar Savić, Slavica Ristić, Nadežda Nikolić, Aleksandar Vukadinović, Tibor J. Sabo, Sanja Vranješ-Đurić PP28 90Y-labeled magnetite nanoparticles for possible application in cancer therapy S. Vranješ-Đurić, M. Radović, D. Janković, N. Nikolić, G. F. Goya, P. Calatayud, V. Spasojević, B. Antić PP29 Simplified automation of the GMP production of 68Ga-labelled peptides David Goblet, Cristiana Gameiro, Neva Lazarova PP30 Combining commercial production of multi-products in a GMP environment with Clinical & R&D activities Cristiana Gameiro, Ian Oxley, Antero Abrunhosa, Vasko Kramer, Maria Vosjan, Arnold Spaans PP31 99mTc(CO)3-labeling and Comparative In-Vivo Evaluation of Two Clicked cRGDfK Peptide Derivatives Kusum Vats, Drishty Satpati, Haladhar D Sarma, Sharmila Banerjee PP32 Application of AnaLig resin for 99mTc separation from molybdenum excess Wojdowska W., Pawlak D.W., Parus L. J., Garnuszek P., Mikołajczak R. PP33 Constraints for selection of suitable precursor for one-step automated synthesis of [18F]FECNT, the dopamine transporter ligand Pijarowska-Kruszyna J, Jaron A, Kachniarz A, Malkowski B, Garnuszek P, Mikolajczak R PP34 Gamma scintigraphy studies with 99mTc- amoxicillin sodium in bacterially infected and sterile inflamed rats Derya Ilem-Ozdemir, Oya Caglayan-Orumlu, Makbule Asikoglu PP35 Preparation of 99mTc- Amoxicillin Sodium Lyophilized Kit Derya Ilem-Ozdemir, Oya Caglayan-Orumlu, Makbule Asikoglu PP36 Outfits of Tracerlan FXC-PRO for 11C-Labeling Arponen Eveliina, Helin Semi, Saarinen Timo, Vauhkala Simo, Kokkomäki Esa, Lehikoinen Pertti PP37 Microfluidic synthesis of ω-[18F]fluoro-1-alkynes Mariarosaria De Simone, Giancarlo Pascali, Ludovica Carzoli, Mauro Quaglierini, Mauro Telleschi, Piero A. Salvadori PP38 Automated 18F-flumazenil production using chemically resistant disposable cassettes Phoebe Lam, Martina Aistleitner, Reinhard Eichinger, Christoph Artner PP39 The effect of the eluent solutions (TBAHCO3, Kryptand K2.2.2) on the radiochemical yields of 18F-Fluoromethylcholine Surendra Nakka, Hemantha Kumara MC, Al-Qahtani Mohammed PP40 [68Ga]Radiolabeling of short peptide that has a PET imaging potentials Al-Qahtani, Mohammed, Al-Malki, Yousif PP41 Is validation of radiochemical purity analysis in a public hospital in a developing country possible? N Mambilima, SM Rubow PP42 Improved automated radiosynthesis of [18F]FEPPA N. Berroterán-Infante, M. Hacker, M. Mitterhauser, W. Wadsak PP43 Synthesis and initial evaluation of Al18F-RESCA1-TATE for somatostatin receptor imaging with PET Uta Funke, Frederik Cleeren, Joan Lecina, Rodrigo Gallardo, Alfons M. Verbruggen, Guy Bormans PP44 Radiolabeling and SPECT/CT imaging of different polymer-decorated zein nanoparticles for oral administration Rocío Ramos-Membrive, Ana Brotons, Gemma Quincoces, Laura Inchaurraga, Inés Luis de Redín, Verónica Morán, Berta García-García, Juan Manuel Irache, Iván Peñuelas PP45 An analysis of the quality of 68Ga-DOTANOC radiolabelling over a 3 year period Trabelsi, M., Cooper M.S. PP46 In vivo biodistribution of adult human mesenchymal stem cells I (MSCS-ah) labeled with 99MTC-HMPAO administered via intravenous and intra-articular in animal model. Preliminary results Alejandra Abella, Teodomiro Fuente, Antonio Jesús Montellano, Teresa Martínez, Ruben Rabadan, Luis Meseguer-Olmo PP47 Synthesis of [18F]F-exendin-4 with high specific activity Lehtiniemi P, Yim C, Mikkola K, Nuutila P, Solin O PP48 Experimental radionuclide therapy with 177Lu-labelled cyclic minigastrin and human dosimetry estimations von Guggenberg E, Rangger C, Mair C, Balogh L, Pöstényi Z, Pawlak D, Mikołajczak R PP49 Synthesis of radiopharmaceuticals for cell radiolabelling using anion exchange column Socan A, Kolenc Peitl P, Krošelj M, Rangger C, Decristoforo C PP50 [68Ga]peptide production on commercial synthesiser mAIO Collet C., Remy S., Didier R,Vergote T.,Karcher G., Véran N. PP51 Dry kit formulation for efficient radiolabeling of 68Ga-PSMA D. Pawlak, M. Maurin, P. Garnuszek, U. Karczmarczyk, R. Mikołajczak PP52 Development of an experimental method using Cs-131 to evaluate radiobiological effects of internalized Auger-electron emitters Pil Fredericia, Gregory Severin, Torsten Groesser, Ulli Köster, Mikael Jensen PP53 Preclinical comparative evaluation of NOTA/NODAGA/DOTA CYCLO-RGD peptides labelled with Ga-68 R. Leonte, F. D. Puicea, A. Raicu, E. A. Min, R. Serban, G. Manda, D. Niculae PP54 Synthesizer- and Kit-based preparation of prostate cancer imaging agent 68Ga-RM2 Marion Zerna, Hanno Schieferstein, Andre Müller, Mathias Berndt PP55 Synthesis of pancreatic beta cell-specific [18F]fluoro-exendin-4 via strain-promoted aza-dibenzocyclooctyne/azide cycloaddition Cheng-Bin Yim, Kirsi Mikkola, Pirjo Nuutila, Olof Solin PP56 Automated systems for radiopharmacy D. Seifert, J. Ráliš, O. Lebeda PP57 Simple, suitable for everyday routine use quality control method to assess radionuclidic purity of cyclotron-produced 99mTc Svetlana V. Selivanova, Helena Senta, Éric Lavallée, Lyne Caouette, Éric Turcotte, Roger Lecomte PP58 Effective dose estimation using Monte Carlo simulation for patients undergoing radioiodine therapy Marina Zdraveska Kochovska, Emilija Janjevik Ivanovska, Vesna Spasic Jokic PP59 Chemical analysis of the rituximab radioimmunoconjugates in lyophilized formulations intended for oncological applications Darinka Gjorgieva Ackova, Katarina Smilkov, Petre Makreski, Trajče Stafilov, Emilija Janevik-Ivanovska PP61 The need and benefits of established radiopharmacy in developing African countries Aschalew Alemu, Joel Munene Muchira, David Mwanza Wanjeh, Emilija Janevik-Ivanovska PP62 University Master Program of Radiopharmacy – step forward for Good Radiopharmacy Education Emilija Janevik-Ivanovska, Zoran Zdravev, Uday Bhonsle, Osso Júnior João Alberto, Adriano Duatti, Bistra Angelovska, Zdenka Stojanovska, Zorica Arsova Sarafinovska, Darko Bosnakovski, Darinka Gorgieva-Ackova, Katarina Smilkov, Elena Drakalska, Meera Venkatesh, Rubin Gulaboski PP63 Synthesis and preclinical validations of a novel 18F-labelled RGD peptide prepared by ligation of a 2-cyanobenzothiazole with 1,2-aminothiol to image angiogenesis. Didier J. Colin, James A. H. Inkster, Stéphane Germain, Yann Seimbille
Collapse
|
22
|
Chalon S, Vercouillie J, Guilloteau D, Suzenet F, Routier S. PET tracers for imaging brain α7 nicotinic receptors: an update. Chem Commun (Camb) 2016; 51:14826-31. [PMID: 26359819 DOI: 10.1039/c5cc04536c] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
Positron emission tomography (PET) molecular imaging of brain targets is a powerful tool to diagnose, follow up, and develop treatments and personalized medicine for a number of acute and chronic brain disorders. The availability of β+ emitter tracers labelled with [(11)C] or [(18)F] having optimal characteristics of affinity and selectivity for alpha-7 nicotinic receptors (α7R) has received considerable attention, due to the major implication of these receptors in brain functions. The aim of this review is to identify the interest and need for the in vivo exploration of α7R by PET molecular imaging, which tools are currently available for this and how to progress.
Collapse
Affiliation(s)
- S Chalon
- UMR Inserm U930, Université François-Rabelais de Tours, F-37000 Tours, France.
| | | | | | | | | |
Collapse
|
23
|
Thomas C, Vercouillie J, Doméné A, Tauber C, Kassiou M, Guilloteau D, Destrieux C, Sérrière S, Chalon S. Detection of Neuroinflammation in a Rat Model of Subarachnoid Hemorrhage Using [18F]DPA-714 PET Imaging. Mol Imaging 2016; 15:15/0/1536012116639189. [PMID: 27118758 PMCID: PMC5470081 DOI: 10.1177/1536012116639189] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/30/2015] [Accepted: 12/16/2015] [Indexed: 01/30/2023] Open
Abstract
Subarachnoid hemorrhage (SAH) can lead to delayed cerebral ischemia, which increases the rate of morbidity and mortality. The detection of microglial activation may serve as a biomarker for the identification of patients at risk of this deleterious consequence. We assessed this hypothesis in a rat model of SAH in which the exploration of neuroinflammation related to microglial activation was correlated with the degree of bleeding. We used the rat filament model and evaluated (at 48 hours postsurgery) the intensity of neuroinflammation using positron emission tomography (PET) imaging with the 18-kDa translocator protein (TSPO) tracer [18F]DPA-714, quantitative autoradiography with [3H]PK-11195, and SAH grade by postmortem brain picture. High SAH grades were strongly and positively correlated with in vivo PET imaging of TSPO in the cortex and striatum. In addition, a positive correlation was found in the cortex in TSPO, with densities determined by imaging and autoradiographic approaches. Qualitative immunofluorescence studies indicated that overexpression of TSPO was linked to astrocytic/microglial activation. In this model, PET imaging of TSPO using [18F]DPA-714 appeared to be a relevant index of the degree of bleeding, indicating that this imaging method could be used in human patients to improve the management of patients with SAH.
Collapse
Affiliation(s)
- Clément Thomas
- UMR Inserm U930, Université François-Rabelais de Tours, Tours, France CHRU de Tours, Tours, France
| | | | - Aurélie Doméné
- UMR Inserm U930, Université François-Rabelais de Tours, Tours, France
| | - Clovis Tauber
- UMR Inserm U930, Université François-Rabelais de Tours, Tours, France
| | - Michael Kassiou
- Faculty of Health Sciences, School of Chemistry, University of Sydney, Sydney, Australia
| | - Denis Guilloteau
- UMR Inserm U930, Université François-Rabelais de Tours, Tours, France CHRU de Tours, Tours, France
| | - Christophe Destrieux
- UMR Inserm U930, Université François-Rabelais de Tours, Tours, France CHRU de Tours, Tours, France
| | - Sophie Sérrière
- UMR Inserm U930, Université François-Rabelais de Tours, Tours, France
| | - Sylvie Chalon
- UMR Inserm U930, Université François-Rabelais de Tours, Tours, France
| |
Collapse
|
24
|
Ouach A, Pin F, Bertrand E, Vercouillie J, Gulhan Z, Mothes C, Deloye JB, Guilloteau D, Suzenet F, Chalon S, Routier S. Design of α7 nicotinic acetylcholine receptor ligands using the (het)Aryl-1,2,3-triazole core: Synthesis, in vitro evaluation and SAR studies. Eur J Med Chem 2016; 107:153-64. [DOI: 10.1016/j.ejmech.2015.11.001] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/14/2015] [Revised: 10/30/2015] [Accepted: 11/01/2015] [Indexed: 10/22/2022]
|
25
|
Gourand F, Amini N, Jia Z, Stone-Elander S, Guilloteau D, Barré L, Halldin C. [11C]MADAM Used as a Model for Understanding the Radiometabolism of Diphenyl Sulfide Radioligands for Positron Emission Tomography (PET). PLoS One 2015; 10:e0137160. [PMID: 26367261 PMCID: PMC4569384 DOI: 10.1371/journal.pone.0137160] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/27/2015] [Accepted: 07/22/2015] [Indexed: 11/19/2022] Open
Abstract
In quantitative PET measurements, the analysis of radiometabolites in plasma is essential for determining the exact arterial input function. Diphenyl sulfide compounds are promising PET and SPECT radioligands for in vivo quantification of the serotonin transporter (SERT) and it is therefore important to investigate their radiometabolism. We have chosen to explore the radiometabolic profile of [11C]MADAM, one of these radioligands widely used for in vivo PET-SERT studies. The metabolism of [11C]MADAM/MADAM was investigated using rat and human liver microsomes (RLM and HLM) in combination with radio-HPLC or UHPLC/Q-ToF-MS for their identification. The effect of carrier on the radiometabolic rate of the radioligand [11C]MADAM in vitro and in vivo was examined by radio-HPLC. RLM and HLM incubations were carried out at two different carrier concentrations of 1 and 10 μM. Urine samples after perfusion of [11C]MADAM/MADAM in rats were also analysed by radio-HPLC. Analysis by UHPLC/Q-ToF-MS identified the metabolites produced in vitro to be results of N-demethylation, S-oxidation and benzylic hydroxylation. The presence of carrier greatly affected the radiometabolism rate of [11C]MADAM in both RLM/HLM experiments and in vivo rat studies. The good concordance between the results predicted by RLM and HLM experiments and the in vivo data obtained in rat studies indicate that the kinetics of the radiometabolism of the radioligand [11C]MADAM is dose-dependent. This issue needs to be addressed when the diarylsulfide class of compounds are used in PET quantifications of SERT.
Collapse
Affiliation(s)
- Fabienne Gourand
- Karolinska Institutet, Department of Clinical Neuroscience, Centre for Psychiatric Research, SE-171 76 Stockholm, Sweden
- CEA, DSV/I2BM, LDM-TEP Group, GIP Cyceron, Bd Henri Becquerel, BP 5229, F-14074 Caen, France
- Université de Caen Basse-Normandie, Caen, France
- CNRS, UMR ISTCT 6301, LDM-TEP Group, GIP Cyceron, Caen, France
- * E-mail:
| | - Nahid Amini
- Karolinska Institutet, Department of Clinical Neuroscience, Centre for Psychiatric Research, SE-171 76 Stockholm, Sweden
| | - Zhisheng Jia
- Karolinska Institutet, Department of Clinical Neuroscience, Centre for Psychiatric Research, SE-171 76 Stockholm, Sweden
| | - Sharon Stone-Elander
- Neuroradiology, Karolinska University Hospital, MicroPET and Clinical Neurosciences, Karolinska Institutet SE-171 76 Stockholm, Sweden
| | - Denis Guilloteau
- INSERM U930- Université François Rabelais de Tours, CHRU de Tours, 2 boulevard Tonnellé, 37044 Tours, France
| | - Louisa Barré
- CEA, DSV/I2BM, LDM-TEP Group, GIP Cyceron, Bd Henri Becquerel, BP 5229, F-14074 Caen, France
- Université de Caen Basse-Normandie, Caen, France
- CNRS, UMR ISTCT 6301, LDM-TEP Group, GIP Cyceron, Caen, France
| | - Christer Halldin
- Karolinska Institutet, Department of Clinical Neuroscience, Centre for Psychiatric Research, SE-171 76 Stockholm, Sweden
| |
Collapse
|
26
|
Sérrière S, Doméné A, Vercouillie J, Mothes C, Bodard S, Rodrigues N, Guilloteau D, Routier S, Page G, Chalon S. Assessment of the Protection of Dopaminergic Neurons by an α7 Nicotinic Receptor Agonist, PHA 543613 Using [(18)F]LBT-999 in a Parkinson's Disease Rat Model. Front Med (Lausanne) 2015; 2:61. [PMID: 26389120 PMCID: PMC4556971 DOI: 10.3389/fmed.2015.00061] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/10/2015] [Accepted: 08/17/2015] [Indexed: 12/02/2022] Open
Abstract
The inverse association between nicotine intake and Parkinson’s disease (PD) is well established and suggests that this molecule could be neuroprotective through anti-inflammatory action mediated by nicotinic receptors, including the α7-subtype (α7R). The objective of this study was to evaluate the effects of an agonist of α7R, PHA 543613, on striatal dopaminergic neurodegeneration and neuroinflammation in a rat model of PD induced by 6-hydroxydopamine (6-OHDA) lesion. Adult male Wistar rats were lesioned in the right striatum and assigned to either the PHA group (n = 7) or the Sham group (n = 5). PHA 543613 hydrochloride at the concentration of 6 mg/kg (PHA group) or vehicle (Sham group) was intra-peritoneally injected 2 h before 6-OHDA lesioning and then at days 2, 4, and 6 post-lesion. Positron emission tomography (PET) imaging was performed at 7 days post-lesion using [18F]LBT-999 to quantify the striatal dopamine transporter (DAT). After PET imaging, neuroinflammation was evaluated in same animals in vitro through the measurement of the microglial activation marker 18 kDa translocator protein (TSPO) by quantitative autoradiography with [3H]PK-11195. The DAT density reflecting the integrity of dopaminergic neurons was significantly decreased while the intensity of neuroinflammation measured by TSPO density was significantly increased in the lesioned compared to intact striatum in both groups. However, these both modifications were partially reversed in the PHA group compared to Sham. In addition, a significant positive correlation between the degree of lesion and the intensity of neuroinflammation was evidenced. These findings indicate that PHA 543613 exerts neuroprotective effects on the striatal dopaminergic neurons associated with a reduction in microglial activation in this model of PD. This reinforces the hypothesis that an α7R agonist could provide beneficial effects for the treatment of PD.
Collapse
Affiliation(s)
- Sophie Sérrière
- UMR INSERM U930, Université François Rabelais , Tours , France
| | - Aurélie Doméné
- UMR INSERM U930, Université François Rabelais , Tours , France
| | | | | | - Sylvie Bodard
- UMR INSERM U930, Université François Rabelais , Tours , France
| | - Nuno Rodrigues
- UMR CNRS 7311, Institut de Chimie Organique et Analytique, Université d'Orléans , Orléans , France
| | - Denis Guilloteau
- UMR INSERM U930, Université François Rabelais , Tours , France ; CHRU de Tours, Hopital Bretonneau , Tours , France
| | - Sylvain Routier
- UMR CNRS 7311, Institut de Chimie Organique et Analytique, Université d'Orléans , Orléans , France
| | - Guylène Page
- EA3808 - CiMoTheMA, Université de Poitiers , Poitiers , France
| | - Sylvie Chalon
- UMR INSERM U930, Université François Rabelais , Tours , France
| |
Collapse
|
27
|
Ben Azzouna R, Alshoukr F, Leygnac S, Guez A, Gonzalez W, Rousseaux O, Guilloteau D, Le Guludec D. A new68Ga anionic concentration and purification method for automated synthesis of [68Ga]-DOTA or NODAGA conjugated peptides in high radiochemical purity. J Labelled Comp Radiopharm 2015; 58:403-10. [DOI: 10.1002/jlcr.3316] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/07/2015] [Revised: 06/12/2015] [Accepted: 06/26/2015] [Indexed: 12/20/2022]
Affiliation(s)
- Rana Ben Azzouna
- Nuclear Medicine Department and DHU FIRE; Bichat-Claude Bernard University Hospital, AP-HP; Paris France
- UMR 1148 Inserm; Paris France
- Federation de Recherche en Imagerie Multimodale; Paris 7 University; Paris France
- Pharmacy Department; Bichat Claude Bernard University Hospital, APHP; Paris France
| | - Faisal Alshoukr
- Nuclear Medicine Department and DHU FIRE; Bichat-Claude Bernard University Hospital, AP-HP; Paris France
- UMR 1148 Inserm; Paris France
- Federation de Recherche en Imagerie Multimodale; Paris 7 University; Paris France
| | - Sébastien Leygnac
- Nuclear Medicine Department and DHU FIRE; Bichat-Claude Bernard University Hospital, AP-HP; Paris France
- UMR 1148 Inserm; Paris France
- Federation de Recherche en Imagerie Multimodale; Paris 7 University; Paris France
| | | | | | | | | | - Dominique Le Guludec
- Nuclear Medicine Department and DHU FIRE; Bichat-Claude Bernard University Hospital, AP-HP; Paris France
- UMR 1148 Inserm; Paris France
- Federation de Recherche en Imagerie Multimodale; Paris 7 University; Paris France
| |
Collapse
|
28
|
Jensen P, Feng L, Law I, Svarer C, Knudsen GM, Mikkelsen JD, de Nijs R, Larsen VA, Dyssegaard A, Thomsen G, Fischer W, Guilloteau D, Pinborg LH. TSPO Imaging in Glioblastoma Multiforme: A Direct Comparison Between 123I-CLINDE SPECT, 18F-FET PET, and Gadolinium-Enhanced MR Imaging. J Nucl Med 2015; 56:1386-90. [PMID: 26182972 DOI: 10.2967/jnumed.115.158998] [Citation(s) in RCA: 33] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/08/2015] [Accepted: 07/06/2015] [Indexed: 12/22/2022] Open
Abstract
UNLABELLED Here we compare translocator protein (TSPO) imaging using 6-chloro-2-(4'-(123)I-iodophenyl)-3-(N,N-diethyl)-imidazo[1,2-a]pyridine-3-acetamide SPECT ((123)I-CLINDE) and amino acid transport imaging using O-(2-(18)F-fluoroethyl)-l-tyrosine PET ((18)F-FET) and investigate whether (123)I-CLINDE is superior to (18)F-FET in predicting progression of glioblastoma multiforme (GBM) at follow-up. METHODS Three patients with World Health Organization grade IV GBM were scanned with (123)I-CLINDE SPECT, (18)F-FET PET, and gadolinium-enhanced MR imaging. Molecular imaging data were compared with follow-up gadolinium-enhanced MR images or contrast-enhanced CT scans. RESULTS The percentage overlap between volumes of interest (VOIs) of increased (18)F-FET uptake and (123)I-CLINDE binding was variable (12%-42%). The percentage overlap of MR imaging baseline VOIs was greater for (18)F-FET (79%-93%) than (123)I-CLINDE (15%-30%). In contrast, VOIs of increased contrast enhancement at follow-up compared with baseline overlapped to a greater extent with baseline (123)I-CLINDE VOIs than (18)F-FET VOIs (21% vs. 8% and 72% vs. 55%). CONCLUSION Our preliminary results suggest that TSPO brain imaging in GBM may be a useful tool for predicting tumor progression at follow-up and may be less susceptible to changes in blood-brain barrier permeability than (18)F-FET. Larger studies are warranted to test the clinical potential of TSPO imaging in GBM, including presurgical planning and radiotherapy.
Collapse
Affiliation(s)
- Per Jensen
- Neurobiology Research Unit, Rigshospitalet, Copenhagen, Denmark
| | - Ling Feng
- Neurobiology Research Unit, Rigshospitalet, Copenhagen, Denmark
| | - Ian Law
- Department of Clinical Physiology, Nuclear Medicine, and PET, Rigshospitalet, Copenhagen, Denmark
| | - Claus Svarer
- Neurobiology Research Unit, Rigshospitalet, Copenhagen, Denmark
| | - Gitte M Knudsen
- Neurobiology Research Unit, Rigshospitalet, Copenhagen, Denmark
| | | | - Robin de Nijs
- Department of Clinical Physiology, Nuclear Medicine, and PET, Rigshospitalet, Copenhagen, Denmark
| | - Vibeke A Larsen
- Department of Radiology, Rigshospitalet, Copenhagen, Denmark
| | | | - Gerda Thomsen
- Neurobiology Research Unit, Rigshospitalet, Copenhagen, Denmark
| | - Walter Fischer
- Department of Neurosurgery, Rigshospitalet, Copenhagen, Denmark
| | - Denis Guilloteau
- Université François-Rabelais de Tours, INSERM U930 "Imaging and Brain," Tours, France; and
| | - Lars H Pinborg
- Neurobiology Research Unit, Rigshospitalet, Copenhagen, Denmark Epilepsy Clinic, Department of Neurology, Rigshospitalet, Copenhagen, Denmark
| |
Collapse
|
29
|
Sérrière S, Tauber C, Vercouillie J, Mothes C, Pruckner C, Guilloteau D, Kassiou M, Doméné A, Garreau L, Page G, Chalon S. Amyloid load and translocator protein 18 kDa in APPswePS1-dE9 mice: a longitudinal study. Neurobiol Aging 2015; 36:1639-1652. [PMID: 25680265 DOI: 10.1016/j.neurobiolaging.2014.11.023] [Citation(s) in RCA: 40] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/15/2014] [Revised: 11/03/2014] [Accepted: 11/25/2014] [Indexed: 12/16/2022]
Abstract
We studied concomitantly the level of neuroinflammation and β-amyloid (Aβ) load in the APPswePS1dE9 transgenic mouse model of Alzheimer's disease using positron emission tomography. The translocator protein 18 kDa (TSPO) tracer [(18)F]DPA-714 was used to measure neuroinflammation and [(18)F]AV-45 for Aβ load in mice at 6, 9, 12, 15, and 19 months of age. At 19 months, we also analyzed the neuroinflammatory and neuroanatomic status of mice brains. The main affected brain areas were the cortex and hippocampus, with a concomitant progression of neuroinflammation with increased amyloid burden. At 19 months, no increase in TSPO binding was observed in the cerebellum; immunostaining revealed W0-2-positive plaques, indicating that the amyloid deposits seemed not stimulate inflammation. This finding was in agreement with the observed level of microglia and astrocytes staining. Our findings provide a better understanding of the relationships between neuroinflammation and plaque accumulation in the course of the disease in this mouse model. The monitoring of both processes should be of value to validate potential therapeutic approaches.
Collapse
Affiliation(s)
- Sophie Sérrière
- UMR Inserm U930, Université François-Rabelais de Tours, Tours, France
| | - Clovis Tauber
- UMR Inserm U930, Université François-Rabelais de Tours, Tours, France
| | | | | | | | - Denis Guilloteau
- UMR Inserm U930, Université François-Rabelais de Tours, Tours, France; CHRU de Tours, Tours, France
| | - Michael Kassiou
- School of Chemistry and Faculty of Health Sciences, University of Sydney, Sydney, Australia
| | - Aurélie Doméné
- UMR Inserm U930, Université François-Rabelais de Tours, Tours, France
| | - Lucette Garreau
- UMR Inserm U930, Université François-Rabelais de Tours, Tours, France
| | - Guylène Page
- EA 3808 CiMoTheMA, Université de Poitiers, Poitiers, France
| | - Sylvie Chalon
- UMR Inserm U930, Université François-Rabelais de Tours, Tours, France.
| |
Collapse
|
30
|
Beaufils E, Ribeiro MJ, Vierron E, Vercouillie J, Dufour-Rainfray D, Cottier JP, Camus V, Mondon K, Guilloteau D, Hommet C. The Pattern of Brain Amyloid Load in Posterior Cortical Atrophy Using (18)F-AV45: Is Amyloid the Principal Actor in the Disease? Dement Geriatr Cogn Dis Extra 2014; 4:431-41. [PMID: 25538727 PMCID: PMC4264487 DOI: 10.1159/000363761] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022] Open
Abstract
Background Posterior cortical atrophy (PCA) is characterized by progressive higher-order visuoperceptual dysfunction and praxis declines. This syndrome is related to a number of underlying diseases, including, in most cases, Alzheimer's disease (AD). The aim of this study was to compare the amyloid load with 18F-AV45 positron emission tomography (PET) between PCA and AD subjects. Methods We performed 18F-AV45 PET, cerebrospinal fluid (CSF) biomarker analysis and a neuropsychological assessment in 11 PCA patients and 12 AD patients. Results The global and regional 18F-AV45 uptake was similar in the PCA and AD groups. No significant correlation was observed between global 18F-AV45 uptake and CSF biomarkers or between regional 18F-AV45 uptake and cognitive and affective symptoms. Conclusion This 18F-AV45 PET amyloid imaging study showed no specific regional pattern of cortical 18F-AV45 binding in PCA patients. These results confirm that a distinct clinical phenotype in amnestic AD and PCA is not related to amyloid distribution.
Collapse
Affiliation(s)
- Emilie Beaufils
- CHRU Bretonneau, Université François Rabelais de Tours, France
| | - Maria Joao Ribeiro
- CHRU Bretonneau, Université François Rabelais de Tours, France ; INSERM U930, Imagerie et Cerveau, Université François Rabelais de Tours, France
| | | | - Johnny Vercouillie
- INSERM U930, Imagerie et Cerveau, Université François Rabelais de Tours, France
| | - Diane Dufour-Rainfray
- CHRU Bretonneau, Université François Rabelais de Tours, France ; INSERM U930, Imagerie et Cerveau, Université François Rabelais de Tours, France
| | - Jean-Philippe Cottier
- CHRU Bretonneau, Université François Rabelais de Tours, France ; INSERM U930, Imagerie et Cerveau, Université François Rabelais de Tours, France
| | - Vincent Camus
- CHRU Bretonneau, Université François Rabelais de Tours, France ; INSERM U930, Imagerie et Cerveau, Université François Rabelais de Tours, France
| | - Karl Mondon
- CHRU Bretonneau, Université François Rabelais de Tours, France ; INSERM U930, Imagerie et Cerveau, Université François Rabelais de Tours, France
| | - Denis Guilloteau
- CHRU Bretonneau, Université François Rabelais de Tours, France ; INSERM U930, Imagerie et Cerveau, Université François Rabelais de Tours, France
| | - Caroline Hommet
- CHRU Bretonneau, Université François Rabelais de Tours, France ; INSERM U930, Imagerie et Cerveau, Université François Rabelais de Tours, France
| |
Collapse
|
31
|
Jaouen V, González P, Stute S, Guilloteau D, Chalon S, Buvat I, Tauber C. Variational segmentation of vector-valued images with gradient vector flow. IEEE Trans Image Process 2014; 23:4773-4785. [PMID: 25203991 DOI: 10.1109/tip.2014.2353854] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/03/2023]
Abstract
In this paper, we extend the gradient vector flow field for robust variational segmentation of vector-valued images. Rather than using scalar edge information, we define a vectorial edge map derived from a weighted local structure tensor of the image that enables the diffusion of the gradient vectors in accurate directions through the 4D gradient vector flow equation. To reduce the contribution of noise in the structure tensor, image channels are weighted according to a blind estimator of contrast. The method is applied to biological volume delineation in dynamic PET imaging, and validated on realistic Monte Carlo simulations of numerical phantoms as well as on real images.
Collapse
|
32
|
Hommet C, Mondon K, Camus V, Ribeiro MJ, Beaufils E, Arlicot N, Corcia P, Paccalin M, Minier F, Gosselin T, Page G, Guilloteau D, Chalon S. Neuroinflammation and β amyloid deposition in Alzheimer's disease: in vivo quantification with molecular imaging. Dement Geriatr Cogn Disord 2014; 37:1-18. [PMID: 24107621 DOI: 10.1159/000354363] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Accepted: 06/17/2013] [Indexed: 11/19/2022] Open
Abstract
BACKGROUND/AIMS Neuroinflammation plays a crucial role in the pathogenesis of Alzheimer's disease (AD). Its relationship with underlying β amyloid deposition remains unclear. In vivo visualization of microglial activation has become possible with the development of molecular imaging ligands when used with positron emission tomography (PET). The translocator protein (TSPO) is upregulated during neuroinflammation. Consequently, targeting TSPO with radiolabeled ligands for PET is an attractive biomarker for neuroinflammation. METHODS A review of the research literature on PET imaging which studied in vivo neuroinflammation in AD subjects and its relationship with amyloid load was performed, including papers published between 2001 and 2012. RESULTS Six studies were included using either [(11)C]PK-11195 or another non-TSPO radioligand that binds to the monoaminooxidase B. All the studies evaluated amyloid load with [(11)C]PIB. Microglial activation and astrocytosis are potentially early phenomena in AD. However, the individual levels of amyloid deposition and microglial activation were not correlated. CONCLUSION Noninvasive in vivo molecular imaging to visualize neuroinflammation in AD may contribute to our understanding of the kinetics of neuroinflammation and its relationship to the hallmarks of the disease. Both are important for the development of future therapeutic modalities and for quantifying the efficacy of future disease-modifying treatments.
Collapse
Affiliation(s)
- C Hommet
- Memory Clinic (CMRR), Tours University Hospita, Tours, France
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
33
|
Ribeiro MJ, Vercouillie J, Debiais S, Cottier JP, Bonnaud I, Camus V, Banister S, Kassiou M, Arlicot N, Guilloteau D. Could (18) F-DPA-714 PET imaging be interesting to use in the early post-stroke period? EJNMMI Res 2014; 4:28. [PMID: 25006546 PMCID: PMC4077629 DOI: 10.1186/s13550-014-0028-4] [Citation(s) in RCA: 35] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/27/2014] [Accepted: 05/07/2014] [Indexed: 12/13/2022] Open
Abstract
Background Cerebral stroke is a severe and frequent condition that requires rapid and reliable diagnosis. If administered shortly after the first symptoms manifest themselves, IV thrombolysis has been shown to increase the functional prognosis by restoring brain reperfusion. However, a better understanding of the pathophysiology of stroke should help to identify potential new therapeutic targets. Stroke is known to induce an inflammatory brain reaction that involves overexpression of the 18-kDa translocator protein (TSPO) in glial cells and infiltrated leukocytes, which can be visualised by positron emission tomography (PET). We aimed to evaluate post-stroke neuroinflammation using the PET TSPO radioligand 18 F-DPA-714. Methods Nine patients underwent 18 F-DPA-714 PET and magnetic resonance imaging (MRI) between 8 and 18 days after the ictus. Co-registration of MRI and PET images was used to define three volumes of interest (VOIs): core infarction, contralateral region, and cerebellum ipsilateral to the stroke lesion. Time activity curves were obtained from each VOI, and ratios of mean and maximum activities between the VOIs were calculated. Results We observed an increased uptake of 18 F-DPA-714 co-localised with the infarct tissue and extension beyond the region corresponding to the damage in the blood brain barrier. No correlation was identified between 18 F-DPA-714 uptake and infarct volume. 18 F-DPA-714 uptake in ischemic lesion (mainly associated with TSPO expression in the infarct area and in the surrounding neighbourhood) slowly decreased from 10 min pi to the end of the PET acquisition, remaining higher than that in both contralateral region and ipsilateral cerebellum. Conclusion Our results show that 18 F-DPA-714 uptake after acute ischemia is mainly associated with TSPO expression in the infarct area and in the surrounding neighbourhood. We also demonstrated that the kinetics of 18 F-DPA-714 differs in injured tissue compared to normal tissue. Therefore, 18 F-DPA-714 may be useful in assessing the extent of neuroinflammation associated with acute stroke and could also help to predict clinical outcomes and functional recovery, as well as to assess therapeutic strategies, such as the use of neuroprotective/anti-inflammatory drugs.
Collapse
Affiliation(s)
- Maria-Joao Ribeiro
- Université François Rabelais de Tours, Tours, UMR-S930, France ; Inserm U930, University of Tours, Tours 37000, France ; CHRU Tours, Tours 37000, France ; CIC-IT INSERM 806 Ultrasons et Radiopharmaceutiques, Tours, France ; Service de Médecine Nucléaire, Hôpital Bretonneau, 2, Boulevard Tonnellé, Tours CEDEX 37044, France
| | - Johnny Vercouillie
- Université François Rabelais de Tours, Tours, UMR-S930, France ; Inserm U930, University of Tours, Tours 37000, France
| | | | - Jean-Philippe Cottier
- Université François Rabelais de Tours, Tours, UMR-S930, France ; Inserm U930, University of Tours, Tours 37000, France ; CHRU Tours, Tours 37000, France
| | | | - Vincent Camus
- Université François Rabelais de Tours, Tours, UMR-S930, France ; Inserm U930, University of Tours, Tours 37000, France ; CHRU Tours, Tours 37000, France ; CIC INSERM 202, Tours, France
| | - Samuel Banister
- School of Chemistry, University of Sydney, Sydney 2006, New South Wales, Australia ; Brain and Mind Research Institute, Sydney 2050, New South Wales, Australia
| | - Michael Kassiou
- School of Chemistry, University of Sydney, Sydney 2006, New South Wales, Australia ; Brain and Mind Research Institute, Sydney 2050, New South Wales, Australia ; Discipline of Medical Radiation Sciences, University of Sydney, Sydney 2006, New South Wales, Australia
| | - Nicolas Arlicot
- Université François Rabelais de Tours, Tours, UMR-S930, France ; Inserm U930, University of Tours, Tours 37000, France ; CHRU Tours, Tours 37000, France
| | - Denis Guilloteau
- Université François Rabelais de Tours, Tours, UMR-S930, France ; Inserm U930, University of Tours, Tours 37000, France ; CHRU Tours, Tours 37000, France ; CIC-IT INSERM 806 Ultrasons et Radiopharmaceutiques, Tours, France ; CIC INSERM 202, Tours, France
| |
Collapse
|
34
|
Gourand F, Emond P, Bergström JP, Takano A, Gulyás B, Guilloteau D, Barré L, Halldin C. A radiometabolite study of the serotonin transporter PET radioligand [(11)C]MADAM. Nucl Med Biol 2014; 41:501-6. [PMID: 24857865 DOI: 10.1016/j.nucmedbio.2014.03.022] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/25/2014] [Revised: 03/21/2014] [Accepted: 03/24/2014] [Indexed: 11/15/2022]
Abstract
INTRODUCTION (11)C]MADAM is a radioligand suitable for PET studies of the serotonin transporter (SERT). Metabolite analysis in human and non-human plasma samples using HPLC separation has shown that [(11)C]MADAM was rapidly metabolized. A possible metabolic pathway is the S-oxidation which could lead to SOMADAM and SO2MADAM. In vitro evaluation of these two potential metabolites has shown that SOMADAM exhibited a good affinity for SERT and a good selectivity for SERT over NET and DAT. METHODS Comparative PET imaging studies in non-human primate brain with [(11)C]MADAM and [(11)C]SOMADAM were carried out, and plasma samples were analyzed using reverse phase HPLC. We have explored the metabolism of [(11)C]MADAM in rat brain with a view to understand its possible interference for brain imaging with PET. RESULTS PET imaging studies in non-human primate brain using [(11)C]SOMADAM indicated that this tracer does not bind with high amounts to brain regions known to be rich in SERT. The fraction of [(11)C]SOMADAM in non-human primate plasma was approximately 5% at 4min and 1% at 15min after [(11)C]MADAM injection. HPLC analysis of brain sample after [(11)C]MADAM injection to rats demonstrated that [(11)C]SOMADAM was not detected in the brain. CONCLUSIONS (11)C]SOMADAM is not superior over [(11)C]MADAM as a SERT PET radioligand. Nevertheless, [(11)C]SOMADAM has been identified as a minor labeled metabolite of [(11)C]MADAM measured in monkey plasma. [(11)C]SOMADAM was not detected in rat brain.
Collapse
Affiliation(s)
- F Gourand
- CEA, DSV/I2BM, LDM-TEP Group, GIP Cyceron, Bd Henri Becquerel, BP 5229, 14074 Caen Cedex, France; Université de Caen Basse-Normandie, Caen, France; CNRS, UMR ISTCT 6301, LDM-TEP Group, GIP Cyceron, Caen, France; Karolinska Institutet, Department of Clinical Neuroscience, Section of Psychiatry, SE-171 76 Stockholm, Sweden.
| | - P Emond
- INSERM U930- Université François Rabelais de Tours, CHRU de Tours, Hopital Bretonneau, 2 boulevard Tonnellé, 37044 Tours, France
| | - J P Bergström
- Karolinska Institutet, Department of Clinical Neuroscience, Section of Psychiatry, SE-171 76 Stockholm, Sweden
| | - A Takano
- Karolinska Institutet, Department of Clinical Neuroscience, Section of Psychiatry, SE-171 76 Stockholm, Sweden
| | - B Gulyás
- Karolinska Institutet, Department of Clinical Neuroscience, Section of Psychiatry, SE-171 76 Stockholm, Sweden
| | - D Guilloteau
- INSERM U930- Université François Rabelais de Tours, CHRU de Tours, Hopital Bretonneau, 2 boulevard Tonnellé, 37044 Tours, France
| | - L Barré
- CEA, DSV/I2BM, LDM-TEP Group, GIP Cyceron, Bd Henri Becquerel, BP 5229, 14074 Caen Cedex, France; Université de Caen Basse-Normandie, Caen, France; CNRS, UMR ISTCT 6301, LDM-TEP Group, GIP Cyceron, Caen, France
| | - C Halldin
- Karolinska Institutet, Department of Clinical Neuroscience, Section of Psychiatry, SE-171 76 Stockholm, Sweden
| |
Collapse
|
35
|
Arlicot N, Tronel C, Bodard S, Garreau L, de la Crompe B, Vandevelde I, Guilloteau D, Antier D, Chalon S. Translocator Protein (18 kDa) Mapping with [
125
I]-CLINDE in the Quinolinic Acid Rat Model of Excitotoxicity: A Longitudinal Comparison with Microglial Activation, Astrogliosis, and Neuronal Death. Mol Imaging 2014. [DOI: 10.2310/7290.2013.00075] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022] Open
Affiliation(s)
- Nicolas Arlicot
- From Inserm, U930; Université François-Rabelais de Tours, UMR-U930; CHRU de Tours, Hôpital Bretonneau, Pôle Santé Publique – Produits de Santé; and CHRU de Tours, Hôpital Bretonneau, Service de Médecine Nucléaire In Vitro, Tours, France
| | - Claire Tronel
- From Inserm, U930; Université François-Rabelais de Tours, UMR-U930; CHRU de Tours, Hôpital Bretonneau, Pôle Santé Publique – Produits de Santé; and CHRU de Tours, Hôpital Bretonneau, Service de Médecine Nucléaire In Vitro, Tours, France
| | - Sylvie Bodard
- From Inserm, U930; Université François-Rabelais de Tours, UMR-U930; CHRU de Tours, Hôpital Bretonneau, Pôle Santé Publique – Produits de Santé; and CHRU de Tours, Hôpital Bretonneau, Service de Médecine Nucléaire In Vitro, Tours, France
| | - Lucette Garreau
- From Inserm, U930; Université François-Rabelais de Tours, UMR-U930; CHRU de Tours, Hôpital Bretonneau, Pôle Santé Publique – Produits de Santé; and CHRU de Tours, Hôpital Bretonneau, Service de Médecine Nucléaire In Vitro, Tours, France
| | - Brice de la Crompe
- From Inserm, U930; Université François-Rabelais de Tours, UMR-U930; CHRU de Tours, Hôpital Bretonneau, Pôle Santé Publique – Produits de Santé; and CHRU de Tours, Hôpital Bretonneau, Service de Médecine Nucléaire In Vitro, Tours, France
| | - Inge Vandevelde
- From Inserm, U930; Université François-Rabelais de Tours, UMR-U930; CHRU de Tours, Hôpital Bretonneau, Pôle Santé Publique – Produits de Santé; and CHRU de Tours, Hôpital Bretonneau, Service de Médecine Nucléaire In Vitro, Tours, France
| | - Denis Guilloteau
- From Inserm, U930; Université François-Rabelais de Tours, UMR-U930; CHRU de Tours, Hôpital Bretonneau, Pôle Santé Publique – Produits de Santé; and CHRU de Tours, Hôpital Bretonneau, Service de Médecine Nucléaire In Vitro, Tours, France
| | - Daniel Antier
- From Inserm, U930; Université François-Rabelais de Tours, UMR-U930; CHRU de Tours, Hôpital Bretonneau, Pôle Santé Publique – Produits de Santé; and CHRU de Tours, Hôpital Bretonneau, Service de Médecine Nucléaire In Vitro, Tours, France
| | - Sylvie Chalon
- From Inserm, U930; Université François-Rabelais de Tours, UMR-U930; CHRU de Tours, Hôpital Bretonneau, Pôle Santé Publique – Produits de Santé; and CHRU de Tours, Hôpital Bretonneau, Service de Médecine Nucléaire In Vitro, Tours, France
| |
Collapse
|
36
|
Tauber C, Beaufils E, Hommet C, Ribeiro MJ, Vercouillie J, Vierron E, Mondon K, Cottier JP, Gissot V, Guilloteau D, Camus V. Brain [18F]FDDNP binding and glucose metabolism in advanced elderly healthy subjects and Alzheimer's disease patients. J Alzheimers Dis 2014; 36:311-20. [PMID: 23609763 DOI: 10.3233/jad-122068] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
BACKGROUND Positron emission tomography (PET) imaging of brain amyloid (Aβ) and neurofibrillary tangle (NFT) load is a candidate biomarker of Alzheimer's disease (AD). OBJECTIVES To compare brain Aβ and NFT load and glucose metabolism in advanced elderly (70 years and older) patients with AD and healthy controls (HCs) by PET with [18F]FDDNP and [18F]FDG. METHODS Seven AD patients (mean ± SD age 79.3 ± 3.6 y, Mini-Mental State Examination (MMSE) score 22.1 ± 2.5) and eight HCs (mean age ± SD, 75.7 ± 3.9 y; MMSE score 29.0 ± 1.2) underwent PET with [18F]FDDNP and [18F]FDG. RESULTS Global [18F]FDDNP uptake was significantly higher (p < 0.05) in AD patients (1.15 ± 0.04) than in HCs (1.10 ± 0.06), while global brain metabolism was lower in AD patients than in HCs (AD patients 0.96 ± 0.09; HCs 1.13 ± 0.11; p < 0.05). In HCs, brain glucose metabolism was correlated with age for both the global [18F]FDG SUVr and in the parietal and posterior cingulate regions, while no correlation was found between age and [18F]FDDNP uptake. In AD patients, global [18F]FDDNP uptake and uptake in the frontal and anterior cingulate regions of interest were correlated with MMSE score, while no correlation was observed with brain glucose metabolism. CONCLUSION Imaging Aβ load and NFT with [18F]FDDNP can distinguish AD patients from HCs in an advanced elderly population. It seems to be less sensitive than [18F]FDG to the brain changes observed with normal aging, but more sensitive to cognitive decline in advanced elderly AD patients.
Collapse
Affiliation(s)
- Clovis Tauber
- Université François Rabelais de Tours & INSERM U930, Tours, France
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
37
|
Arlicot N, Tronel C, Bodard S, Garreau L, de la Crompe B, Vandevelde I, Guilloteau D, Antier D, Chalon S. Translocator protein (18 kDa) mapping with [125I]-CLINDE in the quinolinic acid rat model of excitotoxicity: a longitudinal comparison with microglial activation, astrogliosis, and neuronal death. Mol Imaging 2014; 13:4-11. [PMID: 24622813] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/03/2023] Open
Abstract
Excitotoxicity leads to an inflammatory reaction involving an overexpression of: translocator protein 18 kDa (TSPO) in cerebral microglia and astrocytes. Therefore, we performed ex vivo explorations with [125]-CLINDE, a TSPO-specific radioligand, to follow the time course of TSPO expression, in parallel with lesion progression, over 90 days after induction of cerebral excitotoxicity in rats intrastriatally injected with quinolinic acid. Biodistribution data showed a significant increase in CLINDE uptake on the injured side from 1 days postlesion (dpl); the maximal striatal binding values evidenced a plateau between 7 and 30 dpl. [125I]-CLINDE binding was displaced from the lesion by PK11195, suggesting TSPO specificity. These results were confirmed by ex vivo autoradiography. Combined immunohistochemical studies showed a marked increase in microglial expression in the lesion, peaking at 14 dpl, and astrocytic reactivity enhanced at 7 and 14 dpl, whereas a prominent neuronal cell loss was observed. At 90 dpl, CLINDE binding and immunoreactivity targeting activated microglia, astrogliosis, and neuronal cell density returned to a basal level. These results show that both neuroinflammation and neuronal loss profiles occurred concomitantly and appeared to be transitory processes. These findings provide the possibility of a therapeutic temporal window to compare the differential effects of antiinflammatory treatments in slowing down neurodegeneration in this rodent model, with potential applications to humans.
Collapse
|
38
|
Dufour-Rainfray D, Beaufils E, Vourc'h P, Vierron E, Mereghetti L, Gendrot C, Hommet C, Andres CR, Guilloteau D, Mondon K. Total Protein Level in Cerebrospinal Fluid is Stable in Elderly Adults. J Am Geriatr Soc 2013; 61:1819-21. [DOI: 10.1111/jgs.12489] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Affiliation(s)
- Diane Dufour-Rainfray
- Nuclear Medicine Laboratory; Centre Hospitalier Régional Universitaire; Tours France
- Université François-Rabelais de Tours; PRES Centre-Val de Loire Université; Tours France
- UMR INSERM U 930 Imagerie et cerveau; Université François-Rabelais de Tours; PRES Centre-Val de Loire Université; Tours France
| | - Emilie Beaufils
- Université François-Rabelais de Tours; PRES Centre-Val de Loire Université; Tours France
- Memory Clinic; Centre Hospitalier Régional Universitaire; Tours France
| | - Patrick Vourc'h
- Université François-Rabelais de Tours; PRES Centre-Val de Loire Université; Tours France
- UMR INSERM U 930 Imagerie et cerveau; Université François-Rabelais de Tours; PRES Centre-Val de Loire Université; Tours France
- Biochemical and Molecular Biology Laboratory; Centre Hospitalier Régional Universitaire; Tours France
| | - Emilie Vierron
- Université François-Rabelais de Tours; PRES Centre-Val de Loire Université; Tours France
- UMR INSERM U 930 Imagerie et cerveau; Université François-Rabelais de Tours; PRES Centre-Val de Loire Université; Tours France
| | - Laurent Mereghetti
- Bacteriology and Virology Service; Centre Hospitalier Régional Universitaire; Tours France
- UMR1282 Infectiologie et Santé Publique; Equipe “Bactéries et risque materno-foetal”; Université François-Rabelais de Tours; Tours France
| | - Chantal Gendrot
- Biochemical and Molecular Biology Laboratory; Centre Hospitalier Régional Universitaire; Tours France
| | - Caroline Hommet
- Université François-Rabelais de Tours; PRES Centre-Val de Loire Université; Tours France
- UMR INSERM U 930 Imagerie et cerveau; Université François-Rabelais de Tours; PRES Centre-Val de Loire Université; Tours France
- Memory Clinic; Centre Hospitalier Régional Universitaire; Tours France
| | - Christian R. Andres
- Université François-Rabelais de Tours; PRES Centre-Val de Loire Université; Tours France
- UMR INSERM U 930 Imagerie et cerveau; Université François-Rabelais de Tours; PRES Centre-Val de Loire Université; Tours France
- Biochemical and Molecular Biology Laboratory; Centre Hospitalier Régional Universitaire; Tours France
| | - Denis Guilloteau
- Nuclear Medicine Laboratory; Centre Hospitalier Régional Universitaire; Tours France
- Université François-Rabelais de Tours; PRES Centre-Val de Loire Université; Tours France
- UMR INSERM U 930 Imagerie et cerveau; Université François-Rabelais de Tours; PRES Centre-Val de Loire Université; Tours France
| | - Karl Mondon
- UMR INSERM U 930 Imagerie et cerveau; Université François-Rabelais de Tours; PRES Centre-Val de Loire Université; Tours France
- Memory Clinic; Centre Hospitalier Régional Universitaire; Tours France
| |
Collapse
|
39
|
Beaufils E, Joao‐Ribeiro M, Mondon K, Payoux P, Eustache F, Vercouillie J, Camus V, Guilloteau D, Hommet C. P3–120: PET with 18F‐AV‐45 (florbetapir) in posterior cortical atrophy. Alzheimers Dement 2013. [DOI: 10.1016/j.jalz.2013.05.1191] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Affiliation(s)
| | | | | | - Pierre Payoux
- Institut National de la Santè et de la Recherche Médicale Toulouse France
| | - Francis Eustache
- INSERM, Université de Caen Basse‐Normandie Ecole Pratique des Hautes Etudes, Chu de Caen Caen France
| | | | | | | | | |
Collapse
|
40
|
Beaufils E, Dufour-Rainfray D, Hommet C, Brault F, Cottier JP, Ribeiro MJ, Mondon K, Guilloteau D. Confirmation of the amyloidogenic process in posterior cortical atrophy: value of the Aβ42/Aβ40 ratio. J Alzheimers Dis 2013; 33:775-80. [PMID: 22986776 DOI: 10.3233/jad-2012-121267] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
Posterior cortical atrophy (PCA) is characterized by progressive higher-order visuo-perceptual dysfunction and praxis declines. This syndrome is related to several underlying diseases, including Alzheimer's disease (AD), sometimes involving an amyloidogenic process. The aims of the study were to 1) define cerebrospinal fluid (CSF) biomarker profiles in PCA patients compared to AD patients and 2) explore the amyloidogenic process through the Aβ(42)/Aβ(40) ratio in PCA patients to elucidate the underlying disease in vivo. CSF biomarker analysis (t-tau, p-tau, Aβ(42), and Aβ(42)/Aβ(40) ratio) and neuropsychological examination were performed in 22 PCA patients and compared with those of age-matched AD patients. Associated clinical neurological signs were investigated (e.g., extrapyramidal motor signs, myoclonus). CSF biomarker profiles did not differ significantly between the PCA and AD groups; 82% of patients with PCA fulfilled the biological criteria for typical AD with abnormal levels of the three markers and 18% of PCA patients presented atypical CSF profiles. All PCA patients with associated clinical neurological signs presented typical AD CSF profiles. The clinical presentations of these patients were similar to other PCA subjects. The Aβ(42)/Aβ(40) ratio for all PCA patients, including those with atypical CSF profiles, was decreased. Most PCA syndromes were associated with CSF biomarkers suggestive of AD, even in cases with associated clinical neurological signs. The amyloidogenic process was confirmed by the decreased Aβ(42)/Aβ(40) ratio for all patients. This analysis avoids misdiagnosis in the presence of physiologically high or low amyloid peptide production rates and provides information in vivo to improve understanding of the underlying disease in PCA.
Collapse
|
41
|
Martins AF, Morfin JF, Kubíčková A, Kubíček V, Buron F, Suzenet F, Salerno M, Lazar AN, Duyckaerts C, Arlicot N, Guilloteau D, Geraldes CFGC, Tóth É. PiB-Conjugated, Metal-Based Imaging Probes: Multimodal Approaches for the Visualization of β-Amyloid Plaques. ACS Med Chem Lett 2013; 4:436-40. [PMID: 24900692 DOI: 10.1021/ml400042w] [Citation(s) in RCA: 42] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/31/2013] [Accepted: 04/14/2013] [Indexed: 01/19/2023] Open
Abstract
In an effort toward the visualization of β-amyloid plaques by in vivo imaging techniques, we have conjugated an optimized derivative of the Pittsburgh compound B (PiB), a well-established marker of Aβ plaques, to DO3A-monoamide that is capable of forming stable, noncharged complexes with different trivalent metal ions including Gd(3+) for MRI and (111)In(3+) for SPECT applications. Proton relaxivity measurements evidenced binding of Gd(DO3A-PiB) to the amyloid peptide Aβ1-40 and to human serum albumin, resulting in a two- and four-fold relaxivity increase, respectively. Ex vivo immunohistochemical studies showed that the DO3A-PiB complexes selectively target Aβ plaques on Alzheimer's disease human brain tissue. Ex vivo biodistribution data obtained for the (111)In-analogue pointed to a moderate blood-brain barrier (BBB) penetration in adult male Swiss mice (without amyloid deposits) with 0.36% ID/g in the cortex at 2 min postinjection.
Collapse
Affiliation(s)
- André F. Martins
- Centre de Biophysique Moléculaire, CNRS, Rue Charles Sadron, 45071 Orléans Cedex
2, France
- Department of
Life Sciences,
Center of Neurosciences and Cell Biology (CNC), and Coimbra Chemistry
Center, University of Coimbra, Portugal
| | - Jean-François Morfin
- Centre de Biophysique Moléculaire, CNRS, Rue Charles Sadron, 45071 Orléans Cedex
2, France
| | - Anna Kubíčková
- Centre de Biophysique Moléculaire, CNRS, Rue Charles Sadron, 45071 Orléans Cedex
2, France
- Department of Analytical Chemistry, Charles University in Prague, Albertov 2030, 12840
Prague, Czech Republic
| | - Vojtěch Kubíček
- Centre de Biophysique Moléculaire, CNRS, Rue Charles Sadron, 45071 Orléans Cedex
2, France
| | - Frédéric Buron
- Institut de Chimie Organique
et Analytique, UMR 7311 CNRS/Université d’Orléans, rue de Chartres, 45067 Orléans, France
| | - Franck Suzenet
- Institut de Chimie Organique
et Analytique, UMR 7311 CNRS/Université d’Orléans, rue de Chartres, 45067 Orléans, France
| | - Milena Salerno
- Laboratoire CSPBAT, CNRS UMR
7244, UFR-SMBH, Université Paris 13, 74 rue Marcel Cachin, 93017 Bobigny, France
| | - Adina N. Lazar
- Centre de Recherche de l’Institut
du Cerveau et de la Moelle, CNRS UMR7225, INSERM, UMR975 and UPMC, Hôpital de la Pitié-Salpêtrière 47, Bd de l’Hôpital 75013 Paris, France
| | - Charles Duyckaerts
- Centre de Recherche de l’Institut
du Cerveau et de la Moelle, CNRS UMR7225, INSERM, UMR975 and UPMC, Hôpital de la Pitié-Salpêtrière 47, Bd de l’Hôpital 75013 Paris, France
| | - Nicolas Arlicot
- Inserm, U930, Université François Rabelais de Tours, CHRU de Tours, 37044
Tours Cedex 9, France
| | - Denis Guilloteau
- Inserm, U930, Université François Rabelais de Tours, CHRU de Tours, 37044
Tours Cedex 9, France
| | - Carlos F. G. C. Geraldes
- Department of
Life Sciences,
Center of Neurosciences and Cell Biology (CNC), and Coimbra Chemistry
Center, University of Coimbra, Portugal
| | - Éva Tóth
- Centre de Biophysique Moléculaire, CNRS, Rue Charles Sadron, 45071 Orléans Cedex
2, France
| |
Collapse
|
42
|
Poisnel G, Dhilly M, Moustié O, Delamare J, Abbas A, Guilloteau D, Barré L. PET imaging with [18F]AV-45 in an APP/PS1-21 murine model of amyloid plaque deposition. Neurobiol Aging 2012; 33:2561-71. [DOI: 10.1016/j.neurobiolaging.2011.12.024] [Citation(s) in RCA: 47] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/20/2011] [Revised: 12/15/2011] [Accepted: 12/20/2011] [Indexed: 10/14/2022]
|
43
|
Mazère J, Meissner WG, Mayo W, Sibon I, Lamare F, Guilloteau D, Tison F, Allard M. Progressive supranuclear palsy: in vivo SPECT imaging of presynaptic vesicular acetylcholine transporter with [123I]-iodobenzovesamicol. Radiology 2012; 265:537-43. [PMID: 23012462 DOI: 10.1148/radiol.12112650] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/20/2023]
Abstract
PURPOSE To evaluate the integrity of brain cholinergic pathways in vivo in patients with progressive supranuclear palsy (PSP) by measuring the vesicular acetylcholine transporter expression at single photon emission computed tomography (SPECT) with [123I]-iodobenzovesamicol. MATERIALS AND METHODS All participants provided informed written consent according to institutional human ethics committee guidelines. Ten patients with PSP and 12 healthy volunteers underwent dynamic [123I]-iodobenzovesamicol SPECT and magnetic resonance (MR) imaging. CT and MR images were used to register the dynamic SPECT image to the Montreal Neurologic Institute brain template, which includes the regions of interest of the striatum and the septo-hippocampal, innominato-cortical, and ponto-thalamic cholinergic pathways. For each region of interest, pharmacokinetic modeling of regional time activity curves was used to calculate [123I]-iodobenzovesamicol to vesicular acetylcholine transporter binding potential value, proportional to vesicular acetylcholine transporter expression. RESULTS When compared with control participants, patients with PSP had binding potential values that were unchanged in the striatum and septohippocampal pathway, significantly lower in the anterior cingulate cortex (P=.017) in the innominatocortical pathway, and significantly decreased in the thalamus (P=.014) in the pontothalamic cholinergic pathway. In addition, binding potential values in the thalamus were positively correlated with those in the pedunculopontine nucleus (ρ=0.81, P<.004) and binding potential values in both the thalamus (ρ=-0.88, P<.001) and pedunculopontine nucleus (ρ=-0.80, P<.010) were inversely correlated with disease duration. CONCLUSION Cholinergic pathways were differentially affected in the PSP group, with a significant alteration of pontothalamic pathways that increased with disease progression at both cell body and terminal levels, while the innominatocortical pathway was only mildly affected, and the septohippocampal pathway and the striatum were both preserved.
Collapse
Affiliation(s)
- Joachim Mazère
- Université de Bordeaux, INCIA, UMR 5287, Talence, France.
| | | | | | | | | | | | | | | |
Collapse
|
44
|
Tarkiainen J, Vercouillie J, Guilloteau D, Gulyás B, Sóvágó J, Cselényi Z, Emond P, Chalon S, Sandell J, Hiltunen J, Farde L, Halldin C. Carbon-11 labelling of madam in two different positions: A highly selective pet radioligand for the serotonin transporter. J Labelled Comp Radiopharm 2012. [DOI: 10.1002/jlcr.2580440167] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
|
45
|
Guéret C, Le Bas MD, Perrio C, Dauphin F, Dhilly M, Chazalviel L, Emond P, Chalon S, Tymciu S, Guilloteau D, Lasne MC, Barré L. Synthesis and radiosynthesis with a positron emitter of EP 00652218, a potent antagonist of NK1 receptor, and of a fluoro analog for in vivo evaluation of the substance P receptor by pet. J Labelled Comp Radiopharm 2012. [DOI: 10.1002/jlcr.2580440199] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
|
46
|
Duval S, Siñeriz F, Arlicot N, Barbier-Chassefière V, Vercouillie J, Delbé J, Papy-Garcia D, Guilloteau D, Barritault D. Développement de radiotraceurs pour l’imagerie moléculaire du microenvironnement matriciel tumoral (HIMIMT). Ing Rech Biomed 2012. [DOI: 10.1016/j.irbm.2012.01.006] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
47
|
Maia S, Arlicot N, Vierron E, Bodard S, Vergote J, Guilloteau D, Chalon S. Longitudinal and parallel monitoring of neuroinflammation and neurodegeneration in a 6-hydroxydopamine rat model of Parkinson's disease. Synapse 2012; 66:573-83. [DOI: 10.1002/syn.21543] [Citation(s) in RCA: 40] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/22/2011] [Accepted: 01/24/2012] [Indexed: 12/20/2022]
|
48
|
Leaver KR, Reynolds A, Bodard S, Guilloteau D, Chalon S, Kassiou M. Effects of translocator protein (18 kDa) ligands on microglial activation and neuronal death in the quinolinic-acid-injected rat striatum. ACS Chem Neurosci 2012; 3:114-9. [PMID: 22860181 DOI: 10.1021/cn200099e] [Citation(s) in RCA: 40] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/11/2011] [Revised: 12/08/2011] [Indexed: 11/28/2022] Open
Abstract
There is evidence that excitotoxicity and prolonged microglial activation are involved in neuronal death in neurodegenerative disorders. Activated microglia express various molecules, including the translocator protein 18 kDa (TSPO; formerly known as the peripheral benzodiazepine receptor) on the outer mitochondrial membrane. The TSPO is a novel target for neuroprotective treatments which aim to reduce microglial activation. The effect of PK 11195 and three other TSPO ligands on the level of microglial activation and neuronal survival was evaluated in a quinolinic acid (QUIN) rat model of excitotoxic neurodegeneration. All three ligands were neuroprotective at a level comparable to PK 11195. All of the ligands decreased microglial activation following the injection of QUIN but had no effect on astrogliosis. Interestingly, we also observed neuroprotective effects from the vehicle, dimethyl sulfoxide (DMSO).
Collapse
Affiliation(s)
- Katherine R. Leaver
- Department of Pharmacology,
Bosch Institute and School of Medical Sciences, University of Sydney, NSW 2006, Australia
- Brain
and Mind Research Institute, University of Sydney, NSW 2050, Australia
- UMR INSERM U930,
CNRS ERL 3106, Université François Rabelais de Tours, Tours, France
| | - Aaron Reynolds
- School of Chemistry, University of Sydney, NSW 2006, Australia
| | - Sylvie Bodard
- UMR INSERM U930,
CNRS ERL 3106, Université François Rabelais de Tours, Tours, France
| | - Denis Guilloteau
- UMR INSERM U930,
CNRS ERL 3106, Université François Rabelais de Tours, Tours, France
| | - Sylvie Chalon
- UMR INSERM U930,
CNRS ERL 3106, Université François Rabelais de Tours, Tours, France
| | - Michael Kassiou
- School of Chemistry, University of Sydney, NSW 2006, Australia
- Brain
and Mind Research Institute, University of Sydney, NSW 2050, Australia
- Discipline of Medical Radiation
Sciences, University of Sydney, NSW 2006,
Australia
| |
Collapse
|
49
|
Le Pogam A, Hatt M, Descourt P, Boussion N, Tsoumpas C, Turkheimer FE, Prunier-Aesch C, Baulieu JL, Guilloteau D, Visvikis D. Evaluation of a 3D local multiresolution algorithm for the correction of partial volume effects in positron emission tomography. Med Phys 2011; 38:4920-3. [PMID: 21978037 DOI: 10.1118/1.3608907] [Citation(s) in RCA: 36] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
Abstract
PURPOSE Partial volume effects (PVEs) are consequences of the limited spatial resolution in emission tomography leading to underestimation of uptake in tissues of size similar to the point spread function (PSF) of the scanner as well as activity spillover between adjacent structures. Among PVE correction methodologies, a voxel-wise mutual multiresolution analysis (MMA) was recently introduced. MMA is based on the extraction and transformation of high resolution details from an anatomical image (MR/CT) and their subsequent incorporation into a low-resolution PET image using wavelet decompositions. Although this method allows creating PVE corrected images, it is based on a 2D global correlation model, which may introduce artifacts in regions where no significant correlation exists between anatomical and functional details. METHODS A new model was designed to overcome these two issues (2D only and global correlation) using a 3D wavelet decomposition process combined with a local analysis. The algorithm was evaluated on synthetic, simulated and patient images, and its performance was compared to the original approach as well as the geometric transfer matrix (GTM) method. RESULTS Quantitative performance was similar to the 2D global model and GTM in correlated cases. In cases where mismatches between anatomical and functional information were present, the new model outperformed the 2D global approach, avoiding artifacts and significantly improving quality of the corrected images and their quantitative accuracy. CONCLUSIONS A new 3D local model was proposed for a voxel-wise PVE correction based on the original mutual multiresolution analysis approach. Its evaluation demonstrated an improved and more robust qualitative and quantitative accuracy compared to the original MMA methodology, particularly in the absence of full correlation between anatomical and functional information.
Collapse
Affiliation(s)
- Adrien Le Pogam
- MRC Clinical Sciences Centre, Hammersmith Hospital Campus, Imperial College, London, UK
| | | | | | | | | | | | | | | | | | | |
Collapse
|
50
|
Abstract
Positron emission tomography (PET) images are corrupted by noise. This is especially true in dynamic PET imaging where short frames are required to capture the peak of activity concentration after the radiotracer injection. High noise results in a possible bias in quantification, as the compartmental models used to estimate the kinetic parameters are sensitive to noise. This paper describes a new post-reconstruction filter to increase the signal-to-noise ratio in dynamic PET imaging. It consists in a spatio-temporal robust diffusion of the 4D image based on the time activity curve (TAC) in each voxel. It reduces the noise in homogeneous areas while preserving the distinct kinetics in regions of interest corresponding to different underlying physiological processes. Neither anatomical priors nor the kinetic model are required. We propose an automatic selection of the scale parameter involved in the diffusion process based on a robust statistical analysis of the distances between TACs. The method is evaluated using Monte Carlo simulations of brain activity distributions. We demonstrate the usefulness of the method and its superior performance over two other post-reconstruction spatial and temporal filters. Our simulations suggest that the proposed method can be used to significantly increase the signal-to-noise ratio in dynamic PET imaging.
Collapse
Affiliation(s)
- C Tauber
- Inserm U930, CNRS ERL3106, Université François Rabelais, Tours, France.
| | | | | | | | | | | | | |
Collapse
|